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Liquid Chromatography – Tandem Mass Spectrometry Techniques for 
Drugs of Abuse as Applied to Bacterial and Forensic Toxicology 
 
Stephanie Marie Martindale 
 
 
The ability of bacterial species to transform complex chemical substances has 
been well documented.  Some of these species are native to the human gastrointestinal 
tract and play an active role in the postmortem decomposition process.  These species 
have potential to cause biotransformations that affect compound-to-metabolite ratios 
within the human body, especially after death.  Postmortem changes such as these 
have rarely been evaluated or taken into consideration but they have potential to supply 
valuable information, especially concerning compound identification and confirmation. 
The purpose of this research was to investigate the effects of Escherichia coli, 
Bacteroides fragilis, and Clostridium perfringens on drugs of abuse, and to compare 
these metabolites to those produced during normal human metabolism.  To analyze and 
quantify these effects, a novel liquid chromatography triple quadrupole tandem mass 
spectrometry method was developed for diazepam, flunitrazepam, and metabolites in 
Reinforced Clostridial Medium.  Reinforced Clostridial Medium is a complex matrix 
designed to provide the nutrients necessary to promote growth of bacterial species, 
particularly Clostridia, other anaerobes, and specimens in clinical samples.  To date, 
similar methods of extraction, quantitation, and analysis of drugs of abuse in a nutrient 
medium matrix have not been published.   
After validation, the method was applied to assess the specific effects of human 
gastrointestinal species on the targeted drugs of abuse.  Experiments explored the 
effects of individual bacterial species as well as a mixed culture on the benzodiazepine 
compounds under anaerobic conditions.  Diazepam and flunitrazepam were selected for 
biotransformation studies because of their potential for abuse and prevalence in 
analysis of both clinical and forensic specimens.  Additionally, the human metabolites 
for these compounds had been previously identified and reference standards were 
commercially available. 
A series of bacterial blanks were prepared in Reinforced Clostridial Medium and 
incubated under experimental conditions.  None of the bacterial specimens produced 
interferences with the target analytes that satisfied peak shape, retention time, ion ratio, 
and limit of quantitation requirements. 
Analyte blanks were also prepared for analysis.  Investigation of analyte blanks 
and the mass balance for the reaction suggested that diazepam performed a partial, 
unassisted degradation when incubated under experimental conditions.  However, 
neither nordiazepam, oxazepam, nor temazepam registered an increase between pre- 
to post-incubation concentrations.  The degradation product was therefore unable to be 
identified under current experimental conditions.  In biotransformation studies, 
 
diazepam showed a decrease in concentration between pre- and post-incubation for the 
Escherichia coli and Bacteroides fragilis series of samples, while changes were minimal 
for Clostridium perfringens and the mixed culture.  Findings suggested that Escherichia 
coli and Bacteroides fragilis were acting on diazepam; however there was no increase 
in concentration for the human metabolites monitored.  The discrepancy in mass 
balance was potentially indicative of a unique bacterial metabolite not produced during 
normal human metabolism.   
Analysis of the flunitrazepam drug blanks likewise exhibited a decrease in 
concentration.  Unlike what was observed in the diazepam blank experiments however, 
there was a corresponding increase in concentration for the 7-aminoflunitrazepam 
metabolite in post-incubation samples.  This accounted for some of the flunitrazepam 
conversion.  In biotransformation studies, samples incubated with Escherichia coli 
demonstrated a greater decrease in flunitrazepam concentration than what was seen in 
analyte blank samples, while Bacteroides fragilis, Clostridium perfringens, and the 
mixed culture resulted in nearly complete conversion of flunitrazepam.  Increased 7-
aminoflunitrazepam concentrations accounted for the majority of the conversion; 
however data suggested production of a minor metabolite that was not monitored in the 
current analysis.   
These experiments served as a pilot study and proof of concept.  Unlike previous 
research, animal models were not required for experimental purposes, which eliminated 
the ethical considerations and guidelines required for animal research.  Frozen stock 
cultures of bacterial samples provided a theoretically endless supply of specimens for 
transformation studies, reducing cost.  The streamlined methodology allowed for 
quantities of experimental variations to be performed in unison, conserving time.  
Extraction procedures, a narrow bore column, and low flow rate for instrumental 
analysis minimized solvent consumption and hazardous waste production, making 
analysis both cost-effective and environmentally friendly. 
The presented experimental methodology serves as a template and can be 
adapted and applied to a realm of possibilities including investigation of natural 
products, biodegradation of agricultural and environmental contaminants, isolation and 
repurpose of native bacterial enzymes, as well as further studies on pharmaceutical 
compounds and drugs of abuse.  An additional method was developed and validated for 
quantitation of cocaine, fentanyl, and metabolites in Reinforced Clostridial Medium, 
which will be applied in similar fashion.  The applications can easily be expanded to 
include alternative bacterial species as well.  Ultimately, this methodology would be 
ideal to study compounds that are too toxic or lethal for animal and human metabolic 
investigations.  This would be particularly useful in military explorations of exposure to 
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Chapter 1: Introduction 
 
 
1.1.0 Background Information 
 
 
Compound detection, identification, confirmation, and quantitation are 
cornerstone principles of analytical and forensic toxicology.  These principles support 
experimental investigations and applications to innovative areas of research and 
development.   
An exploration of previously published literature and research revealed that 
bacteria were capable of metabolizing complex chemical substances such as food 
additives and dyes, environmental contaminants, pharmaceutical compounds, and 
drugs of abuse.  Many of these studies resulted in novel applications toward agricultural 
and environmental contaminant reduction or elimination, greater insight into the 
effectiveness of pharmaceutical compounds, or innovative applications of isolated 
bacterial enzymes. 
Some of these same bacterial species are native to the human body and play an 
active role in the postmortem decomposition process.  After death, these species have 
potential to cause biotransformations that affect the ratio of compound-to-metabolite 
concentrations within the human body.  To date, such postmortem changes have rarely 
been evaluated or taken into consideration, but they have potential to supply valuable 
information, especially concerning compound identification and confirmation.  
The presented experimental methodology can be adapted and applied to a realm 




degradation capabilities for environmental contaminants such as pesticides, explosives, 
and chemical warfare agents, and isolation and repurpose of native bacterial enzymes 
for medical use or analyte detection purposes are just the beginning.  Ultimately, this 
methodology would be ideal to study compounds that are too toxic or lethal for animal 
and human metabolic investigations.  This would be particularly useful in defense and 
military explorations involving exposure to incapacitation and chemical warfare agents, 
especially in circumstances that result in casualties. 
 
1.1.1 Agricultural Applications and Environmental Contaminants 
 
Several studies have investigated the effects of bacterial species on compounds 
found in food as well as environmental contaminants.  Peppercorn and Goldman 
determined that bacterial species isolated from human feces were capable of converting 
caffeic acid, which is present in many foods and coffee, to dihydrocaffeic acid and 
ethylcatechol.1  Metabolites were quantified using gas chromatography-mass 
spectrometry (GC-MS).  The authors discovered that individual bacterial species were 
only able to achieve minimal caffeic acid conversion.  However, they noted increased 
metabolite production in feces for which they concluded conversion of caffeic acid likely 
resulted from a joint effort amongst the multitude of bacterial species present. 
The authors performed a similar set of experiments in which the metabolism of 
caffeic acid was compared between germfree rats, gnobiotic rats, and conventional 
rats.2  Germfree rats were born and maintained in the sterile environment at the 
National Institutes of Health (NIH) Germfree Facility.  Their diet was supplemented with 




Gnobiotic rats are those which are born in germfree conditions, but are 
intentionally inoculated with a specific bacterial specimen or specimens.  In this 
instance, the gnobiotic rats were inoculated with a single strain of Bacteroides sp., 
Lactobacillus sp.1, Lactobacillus sp.2, or Streptococcus group N strain.  The gnobiotic 
rats inoculated with Streptococcus group N strain excreted caffeic acid as well as 
dihydrocaffeic acid.  Importantly, these rats were the only ones capable of transforming 
caffeic acid, and the authors concluded that the Streptococcus group N strain had a 
direct impact on this metabolic ability.  Another set of gnobiotic rats was inoculated with 
all four strains of bacteria.  These rats excreted caffeic acid and dihydrocaffeic acid, as 
well as two additional metabolites. 
Conventional rats exhibited the greatest conversion of caffeic acid to several 
metabolites.  By comparing the metabolites produced by germfree, gnobiotic, and 
conventional rats, the authors concluded that conversion of caffeic acid is affected by 
the bacterial species present in the gastrointestinal (GI) tract of the host organism.   
Islam et al. isolated a mixture of six bacterial genera including Citrobacter, 
Clostridium, Enterococcus, Serratia, Stenotrophomonas, and Streptomyces from soil 
samples collected in crop fields.3  This mixed culture converted deoxynivalenol (DON), a 
contaminant of grains and cereals also known as “vomitoxin”, to de-epoxy DON.  
Conversion occurred rapidly under aerobic conditions, and was monitored using liquid 
chromatography-ultraviolet-mass spectrometry (LC-UV-MS).  The authors proposed that 
this method be applied to decontamination of tainted grain and corn crops.  Methods 




remediation purposes are advantageous because they do not rely on chemical 
compounds and processes that could result in further environmental problems. 
Bharagava and Chandra found that aerobic species Bacillus licheniformis 
(DQ779010), Bacillus sp. (DQ779011), and Alcaligenes sp. (DQ779012) were capable 
of biotransforming the compounds that cause distillery wastewater to appear dark brown 
in color.4  Melanoidins are biopolymeric compounds produced by the Maillard reaction, 
a reaction in which protein and sugar react when heated to produce brown coloration.  
Caramel-colorants produced in the processing of sugarcane juice as well as distillation 
of molasses also contributed to wastewater browning.  Wastewater samples were 
inoculated with a mixture of selected aerobic species, glucose, and peptone.  Changes 
in absorbance which correlated with changes in wastewater coloration were monitored 
with a spectrophotometer.   
The bacterial group was capable of converting approximately 70% of the color 
compounds.  An aliquot of the degraded wastewater sample was purified and analyzed 
via liquid chromatography-tandem mass spectrometry (LC-MS/MS) to identify and 
quantify metabolites produced.  The authors suggested that their method could be an 
effective means of environmental decontamination when applied to detoxification of 
distillery wastewater.  
Mohamed discovered a novel bacterial strain denoted Stenotrophomonas 
maltophilia M1, which was isolated from water sources in Egypt contaminated with 
pesticide residues.5  This strain was capable of degrading methomyl, a toxic pesticide 
used to control insects and other pests, when glucose was present.  Degradation 




ionization-mass spectrometry (SPE-LC-ESI-MS).  Mohamed suggested application of 
M1 in bioremediation of the environment and water sources in areas contaminated with 
methomyl.  
Zhang et al. isolated a bacterial strain capable of efficient nicosulfuron 
degradation. 6  Nicosulfuron is a sulfonylurea herbicide used to control weed growth in 
crop fields and is also a source of groundwater pollution.  Authors determined that 
Serratia marcescens N80 was capable of utilizing nicosulfuron as a sole nitrogen 
source, the effects for which were measured by liquid chromatography-mass 
spectrometry (LC-MS).  They proposed utilization of N80 in future bioremediation 
attempts.  Further analysis revealed that N80 was also capable of degrading several 
other sulfonylurea herbicides as well.  
Rafii et al. determined that Clostridium clostridiiforme, Clostridium leptum, and 
Clostridium paraputrificum, amongst others species possessed a nitroreductase 
capable of converting nitrated polycyclic aromatic hydrocarbons (nitro-PAHs) to various 
aromatic amines.7  Nitro-PAHs are environmental contaminants found in diesel 
emissions, spent motor oil, and urban air and pose human health risks.  Bioconversion 
decreased the mutagenic effects of the nitro-PAH compounds.  The bacterial 
nitroreductase was isolated and purified, and had potential to be an effective 
environmental bioremediation agent for nitro-PAH compounds.  Rafii and Cerniglia also 
investigated a Clostridium perfringens azoreductase capable of cleaving azo dyes such 
as Direct Blue.8,9  
6-nitrochrysene is another nitro-PAH and known carcinogenic compound.  




nitrochrysene to several metabolites.10  However, these products were also thought to 
have negative toxicological capabilities, which hindered the effectiveness of 
environmental remediation efforts.  
Gallagher et al. discovered a Lysobacter-like bacterium capable of using 2,4,6-
trinitrotoluene (TNT) as both a carbon and nitrogen source under anaerobic 
conditions.11  TNT is an explosive compound and persistent environmental contaminant.  
The authors proposed usage of the Lysobacter-like bacterium in future TNT remediation 
efforts.  Similarly, experimental efforts by Nishino, Paoli, and Spain identified a single 
strain of bacteria capable of degrading 2,4-dintrotoluene (2,4-DNT) as well as three 
strains capable of degrading 2,6-dinitrotoluene (2,6-DNT).12  Both of these compounds 
are components of TNT and are often seen as soil and water contaminants near former 
TNT production sites.  Combinations of the Lysobacter-like bacterium as well as the 
species identified by Nishino, Paoli, and Spain may result in more efficient and complete 
remediation efforts.11,12 
Kuntze et al. identified Thauera chlorobenzoica as a specimen capable of 
utilizing organohalides as sole carbon sources under aerobic as well as anaerobic 
conditions.13  These halogenated aromatic compounds are ingredients in insecticides, 
flame retardants, and lubricants and act as sources of negative human health effects as 
well as environmental contaminants.  T. chlorobenzoica degraded these compounds via 





1.1.2 Pharmaceutical Compounds 
In addition to the effects on environmental contaminants, several studies 
demonstrated that some bacterial species are able to transform pharmaceutical 
compounds.  Peppercorn and Goldman performed studies comparing the effects of 
germfree and conventional rats on salicylazosulfapyridine (SAS).14  SAS is a 
pharmaceutical compound consisting of salicylate and sulfa drug components which act 
as anti-bacterial and anti-inflammatory agents, respectively.  It is often used in the 
treatment of ulcerative colitis.  Conventional rats dosed with SAS excreted urine and 
feces samples containing the SAS metabolites 5-aminosalicylate (5AS) and 
sulfapyridine (SP).   
The germfree rat did not originally produce these metabolites.  However, once 
removed from the sterile environment, the rat gained the ability to reduce the azo bonds 
of SAS and produced 5AS and SP.  This study demonstrated that GI bacteria are 
capable of reducing pharmaceutical compounds, which may provide an explanation for 
differences in human responses to pharmaceutical drugs as well as treatment 
effectiveness. 
Metonidazole is a pharmaceutical compound used in the treatment of 
trichomonal vaginitis and anaerobic bacterial infections.  Koch and Goldman compared 
results of germfree and conventional rats, and determined that GI bacteria were 
responsible for the transformation of metonidazole to N-(2-hydroxyethyl)-oxamic acid.15  






1.1.3 Drugs of Abuse 
 
A few studies have described the ability of some bacterial species to transform 
drugs of abuse.  Robertson and Drummer studied the effects of eight GI species 
including Bacteroides fragilis, Bacillus spp., Clostridium perfringens, Escherichia coli, 
Proteus miribalis, Staphylococcus aureus, Staphylococcus epidermidis, and 
Streptococcus faecalis on clonazepam, flunitrazepam, and nitrazepam in blood.16   
Samples were analyzed via high performance liquid chromatography with ultraviolet 
detector (HPLC-UV).17  All three drugs were converted to their respective 7-amino 
metabolites though the rate of metabolism varied between species.16  Effects of pH and 
temperature were examined as well.  Changes in pH affected the rate of metabolism for 
most species, but there was no discernible trend.  However, as temperature increased 
from 4°C to 22°C to 37°C, all eight GI species demonstrated greater efficiency in 
metabolism.  
Bressler et al. isolated a Rhodococcus sp. strain designated as MB1 from soil 
near Erythroxylum coca, the plant from which cocaine is produced.18  Authors 
determined that  MB1 was capable of utilizing cocaine as a sole source of both carbon 
and nitrogen.  Cocaine was hydrolyzed to form ecgonine methyl ester, a metabolite 
commonly seen in human metabolic studies, as well as benzoic acid.  The authors 
extracted the Rhodococcus sp. cocaine esterase and proposed to utilize it in the design 
of a sensor for cocaine detection.  
A strain of Pseudomonas maltophilia (MB11L) was also capable of utilizing 
cocaine as a sole carbon source.19  Britt, Bruce, and Lowe isolated this species from 




MB11L converted cocaine to ecgonine methyl ester and benzoic acid.  Analyses were 
performed using HPLC-UV and gas chromatography with a flame ionization detector 
(GC-FID).  
Brim et al. developed a mutated Rhodococcus cocaine esterase known as DM-
CocE.20, 21  This enzyme hydrolyzed cocaine as well as metabolites norcocaine and 
cocaethylene, but had no effect on benzoylecgonine.  Metabolites were quantified using 
LC-MS/MS.21  The authors aimed to apply the enzyme to the treatment of cocaine 
addiction as well as in treatment of cocaine toxicity as a result of overdose.20,21  
Labroo et al. compared the extent and rate of fentanyl metabolism by human liver 
microsomes and duodenal microorganisms.22  Samples were quantified via GC-MS.  
Both systems converted fentanyl to dealkylated metabolite norfentanyl; however the 
liver performed the conversion twice as quickly.  Cytochrome P450 3A4 was identified 
as the predominant enzyme responsible for the conversion of fentanyl to norfentanyl in 
both the liver and duodenum.  
Cameron et al. isolated a Rhodococcus sp. (H1) from garden soil.23  H1 was 
capable of utilizing heroin as a sole carbon source, hydrolyzing it into morphine.  
Authors planned to purify the heroine esterase and combine it with a previously 
discovered morphine dehydrogenase isolated from Pseudomonas putida  (M10) in an 






The purpose of this research was to investigate the effects of several bacterial 




normal human metabolism.  To analyze and quantify these effects, a novel liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) method was developed for 
analytes of interest as well as the corresponding human metabolites in Reinforced 
Clostridial Medium (RCM).  The method was used to investigate and analyze the 
specific effects of human GI species on the targeted drugs of abuse compounds.  At the 
onset of this research, similar methods of extraction and quantitation of drugs of abuse 
in a nutrient medium matrix and application toward analysis of biotransformation studies 




   
Comparing the metabolites produced by bacteria to those of human metabolism 
was considered a particularly interesting area of exploration.  This research focused on 
the effects of GI bacteria, specifically Escherichia coli, Bacteroides fragilis, and 
Clostridium perfringens on common drugs of abuse.  These bacteria were chosen 
because they are prevalent in the GI tract and have demonstrated biotransformation 
capabilities which are summarized in sections 1.1.1 – 1.1.3.  Preparation and growth of 
these species are discussed in Chapter 2. 
Diazepam (DZ), flunitrazepam (FLU), cocaine (COC), and fentanyl (FENT) were 
chosen as the initial analytes of interest.  They are all classified as drugs of abuse by 
the United States Drug Enforcement Agency (DEA), Schedule II-Schedule IV, and are 
therefore of forensic importance.24  Drug use and overdose are common occurrences, 
and drug selection was based upon compounds for which human metabolism studies 




depicts the analytes of interest as well as the corresponding structure, formula, and 
molecular weight. 
 














































































Analytes were extracted from RCM using solid phase extraction (SPE).  RCM is 
a complex matrix designed to provide the nutrients necessary to promote growth of 
bacterial species, particularly Clostridia, other anaerobes, and specimens encountered 
in clinical samples.  RCM components are detailed in Table 2.  The SPE methods 
focused on reduction of matrix interferences, particularly the salts and polar 
components of the media, which could inhibit effectiveness instrumental analysis. 
 






 10.0 g Beef Extract 
 10.0 g Peptone 
 3.0 g Yeast Extract 
 5.0 g Dextrose 
 5.0 g NaCl 
 3.0 g NaC2H3O2 
 1.0 g Soluble Starch 
 0.5 g Cysteine HCl 




Adjust to 1.0 L  
 
Final pH = 6.8 ± 0.2 
 
Autoclave @121°C  
for 15 minutes. 
   
LC-MS/MS was chosen as the analytical technique for several reasons.  The 
compounds of interest exhibited structural similarities and displayed similar 
fragmentation patterns under common analytical processes.  High performance liquid 
chromatography (HPLC) allowed for selection of both solid (column) and mobile phases 
(buffers) as well as buffer composition, type of elution, flow rate, and column 
temperature to enhance separation and selectivity of the closely related and structurally 




chosen for sensitivity and additional selectivity with mass analysis performed in multiple 
reaction mode (MRM).  Analyte-specific ion transitions were quantified in narrow 
windows corresponding to retention time. 
 
 
1.5.0 Method Validation  
 
 
Compound detection, identification, confirmation, and quantitation are 
cornerstone principles of analytical and forensic toxicology.  These principles support 
development of experimental investigations and applications for innovative areas of 
research and development.  To perform analysis with reliability and certainty, a method 
must be validated.  There are many published guidelines available that discuss 
validation requirements; however, there is a degree of subjectivity to be evaluated by 
the analyst.  Methods development and validation were discussed in Chapter 3 and 
Chapter 5 of this research. 
For method validation, the intended use of the method should dictate the design 
of the validation plan as well as parameter selection.  Validation parameters should be 
examined under the same analytical conditions and using the same SPE and 
instrumental techniques as the final method.  Finally, the parameter definitions and 
validation should be reported so that experiments and analysis could be reasonably 
reproduced by an alternative analyst or laboratory. 
In this research, validation definitions and practices were based upon the 
International Conference on Harmonisation (ICH) guidelines for linearity, specificity, 
accuracy, precision, repeatability, detection limit, quantitation limit, range, and 




Standard Practices for Method Validation in Forensic Toxicology26 and the Guidance for 
Industry: Bioanalytical Method Validation27 produced by the U.S. Department of Health 
and Human Services (DHHS), Food and Drug Administration (FDA), Center for Drug 
Evaluation and Research (CDER), and Center for Veterinary Medicine (CVM) were also 




 Linearity was defined as the method’s ability to achieve responses that are 
directly proportional to analyte concentration within a given range. 27  A calibration 
model was used to address the linearity for each analyte of interest.  Most guidelines 
required four to six points in creation of the calibration curve.26, 27  For purposes of this 
research, calibration models consisted of a 10-point calibration set prepared and 
extracted from RCM.  The 10-point calibration was chosen because it allowed for 
adjustment to the model for each analyte based upon the limit of detection and range, 
while maintaining the requirement of six calibration points.  The curve was constructed 
as a linear model ignoring the origin, and with 1/x weighting.  The correlation coefficient 
(R2) was used to assess the linearity of each analyte in the method.  The calibration 
model was one of the most important validation parameters assessed.  All subsequent 
analysis and quantitation values are all based upon the relationship established in the 
calibration model. 
 
1.5.2 Carryover Effects 
 
Carryover analysis was conducted for a minimum of three concentration levels 




included in the calibration model were also investigated.  An extracted blank was 
injected after each sample and carryover effects were determined by analysis of the 




The specificity of a method was defined as the ability to evaluate the analyte of 
interest in the presence of matrix components or impurities. 27  Specificity was 
determined by conducting interference studies as well as assessing ionization 
suppression/enhancement, matrix effects, recovery, and process efficiency.26    
 
1.5.3.1 Interference Studies 
Ten samples of RCM matrix were prepared, pooled, and autoclaved at 121°C for 
15 minutes.  Blank samples were extracted and then analyzed to assess possible 
interferences between matrix components and the analytes of interest.  Possible 
interferences were identified based upon retention time, peak shape, and ion ratios of 
the target analytes.  Ion ratios were calculated as a ratio of response between 
qualitative ion: quantitative ion.  Blank matrix was also spiked with deuterated standards 
to address possible interferences arising from similar fragmentation patterns of target 
analyte and corresponding deuterated standard. 26  
 
1.5.3.2 Ionization Suppression/Enhancement and Recovery 
 
 Ionization suppression/enhancement studies were combined with matrix effect 
(ME), recovery (RE), and process efficiency (PE) studies.  Analysis was based on 
methods published by SWGTOX26 and  Matuszewski.28  Samples were prepared in 3 




extraction samples for which 1 mL of blank matrix was extracted and dried and then 
spiked with the appropriate amounts of working standard, internal standard, and 
reconstitution buffer to achieve the desired concentration.  In Set C, matrix samples 
were spiked with analytes and internal standards and then extracted, dried, and 
reconstituted in 1 mL of buffer.  Samples were analyzed in triplicate.  The following 
equations were used to calculate the percentage ME as determined by ionization 
suppression or enhancement (Equation 1), RE (Equation 2), PE (Equation 3).  
 
Equation 1 – Matrix Effect (%) 
     
    
    
         
 
Equation 2 – Recovery (%) 
     
     
    
         
 
 
Equation 3 – Process Efficiency (%) 
      
     
    







 Accuracy was defined as the degree of agreement between the experimental and 
theoretical values.27  Accuracy was calculated using Equation 4.26  The acceptable 






Equation 4 – Accuracy (%) 
               
                            
             






The bias of the method was also determined by the agreement between the 
experimental and theoretical values.26  However, bias measures the agreement 
between all the samples at a given concentration level.  The % bias was calculated 
using Equation 5 where the grand mean of [EXP] (experimental concentration) 
represents the average of the entire concentration level and [THEO] is equal to the 
theoretical or known value for that concentration level.  The acceptable range for bias 
was established at ±20% of the theoretical concentration value. 
 
Equation 5 – Bias (%) 
       
                      
      






Precision was defined as the agreement between replicate analyses of the same 
sample. 27  The SWGTOX guidelines referred to this as within-run precision.26 
Data used in bias calculations were also used in precision calculations.  The within-run 
precision was determined by analyzing the triplicate runs for each sample as seen in 
Equation 6 where [Run] represents the mean of the triplicate runs and σR represents 
the standard deviation of the mean between the triplicate runs.  The within-run precision 




CV for each concentration set.  The acceptable range for within-run precision was 
established at ±20% of the theoretical concentration value. 
 
Equation 6 – Within-Run Precision (%CV) 
                
  
      





 Repeatability was defined as a measure of agreement between samples in a 
short period of time under the same operating conditions. 27  The SWGTOX guidelines 
refer to this as between-run precision.26  Between-run precision was determined by 
analyzing the 5 runs at the same concentration level.  Between-run precision was 
calculated using Equation 7 where [Level] represents the grand mean of the 
concentration level and σL represents the standard deviation of the grand mean of all 
the runs at each concentration level.  The between-run precision for the method was 
considered to be highest calculated between-run CV for each concentration level.  The 
acceptable range for between-run precision was established at ±20% of the theoretical 
concentration value. 
 
Equation 7 – Between-Run Precision (%CV) 
                 
  
        
         
 
 
1.5.8 Detection Limit 
 
 Detection limit was defined as the concentration at which an analyte can be 
detected, but is not necessarily able to be quantified. 27  This was also referred to as the 




LOD was determined to be the lowest concentration for which the analyte demonstrates 
acceptable peak shape, retention time, and ion ratios as well as a signal response equal 
to at least three times greater than the background noise response (S/N ≥ 3).  This was 
determined for each analyte. 
 
1.5.9 Quantitation Limit 
 
 The quantitation limit was defined as the lowest concentration for which an 
analyte can be quantified with acceptable accuracy and precision. 27  SWGTOX 
requirements for limit of quantitation (LOQ) included LOD requirements of peak shape, 
retention time, and ion ratios as well as acceptable accuracy and precision.26  This was 





 The range of an analyte was defined as the values between the LOQ and the 
highest calibration value over which a linear response was maintained.27  All method 
calibration curves we prepared according to these guidelines. 
 
1.5.11 Dilution Integrity 
 
Dilution integrity was an important feature of method validation, especially when 
applied sample concentrations exceeded the calibration range of the analyte of 
interest.26  To determine dilution integrity, bias and precision studies were recalculated 
for the diluted samples.  Dilution integrity was analyzed at 1:2, 1:5, and 1:10 ratios.  Five 








1.5.12.1 Freeze-Thaw Stability 
 
Freeze-thaw (FT) stability and processed sample stability were both assessed as 
part of the method validation.26  For freeze-thaw analysis, three samples per 
concentration were prepared in media and frozen for 24 hours.  All of the samples were 
thawed at room temperature.  One vial from each concentration level was extracted and 
analyzed (FT1) while the other two were frozen for an additional 24 hours.  The cycle 
was repeated for FT2 and FT3.  This type of analyte stability was important for samples 
that could not be analyzed immediately and were frozen for preservation. 
 
1.5.12.2 Processed Sample Stability 
 
The stability of processed samples was studied to address possible effects of 
large sample batches or instrument malfunctions that could prevent samples from being 
analyzed immediately.26  Stability studies were conducted at two concentrations, high 
and low.  Two samples were prepared in RCM at each concentration, extracted, 




 Robustness of a method is defined as the ability to remain unaffected as slight 
variations are made to method parameters.25,26  Robustness of the method was 
determined by slight changes in the buffer composition and column temperature.  In 
addition to buffer composition and column temperature, an alternate analyst prepared 










 Anaerobic bacteria endogenous to the human body are active in the postmortem 
decomposition process.  To study the effects of these species on the selected drugs of 
abuse, bacterial methods were developed and optimized.  A nutrient medium, 
environmental and growth conditions, and methods of cellular lysis were selected and 
optimized.  A frozen stock culture was prepared for future experiments and a serial 
dilution and plate count method was used to estimate the number of viable bacteria.  
 
2.2.0 Background  
 
 
 Cellular metabolism is estimated to continue for approximately 4-10 minutes 
postmortem.29  During this interval, carbon dioxide (CO2) begins to accumulate which 
lowers pH.  This continues until the acidity reaches concentrations capable of rupturing 
cellular membranes.  Lysing of these membranes causes the release of digestive 
enzymes, and marks the beginning of the decomposition process.29-31 
 The decomposition process is typically broken down into four stages: autolysis, 
putrefaction, decay, and diagenesis.30,31  In the autolysis or self-digestion phase, cellular 
enzymes begin to dissolve the remaining cellular structures from within.  These 
chemical changes within the cell along with decreasing oxygen and increasing carbon 
dioxide cause waste to accumulate and poison the cell.  Resulting fluids from these 




by endogenous bacteria and microbes, especially those native to the GI tract.  The 
catabolic processes result in production of various gases such as ammonia (NH3), 
methane (CH4), carbon dioxide (CO2), and hydrogen sulfide (H2S) as well as a variety of 
liquid byproducts.  After the soft tissues have been broken down, the body enters decay 
in which remaining protein and fats are decomposed.  The final stage of decomposition 
is diagenesis and is marked by the degradation of bones.  Anaerobic bacteria and 
microbes endogenous to the human body are active in the postmortem decomposition 
process, especially during the putrefaction and decaying phases.30,31  
Indigenous microflora colonize much of the human body both on the surface and 
internally.  Though the intestinal tract is sterile at birth, a “mature” microfloral 
environment is established within 3-4 weeks of life.  The numbers and types of bacteria 
differ between regions of the body based upon pH conditions and the oxygen 
requirements of the microbes themselves.32,33  
Table 3 lists approximations of the number of viable bacteria in each section of 
the GI tract per gram of sample taken.32-34  While a total bacterial count includes both 
living and dead organisms, the viable bacteria count estimates the number of bacteria 
present that are living and able to both grow and divide; thus, capable of metabolic 
activity.32,33 
 









Viable Bacteria/Gram 0 - 103 0 - 104 105 - 108 1010 - 1012 






This research focuses on the lower GI tract, particularly the ileum and colon.  In 
these sections, the oxygen concentration is limited, which promotes the largest 
populations of facultative anaerobic and anaerobic species.  Table 4 contains 
information pertaining to the most abundant facultative anaerobic and obligate 
anaerobic bacteria endogenous to the human intestinal tract.  It also includes basic 
information pertaining to Gram-stain, morphology, and oxygen requirements for each 
species. 32,35 
 









Bacteroides sp. - Bacillus Obligate Anaerobe 
Clostridium sp. + Bacillus Obligate Anaerobe 
Enterococcus faecalis - Coccus Facultative Anaerobe 
Escherichia coli - Bacillus Facultative Anaerobe 
Proteus sp. - Bacillus Facultative Anaerobe 
Staphylococcus aureus + Coccus Facultative Anaerobe 
Staphylococcus epidermidis + Coccus Facultative Anaerobe 
Streptococcus mitis + Coccus Facultative Anaerobe 
Streptococcus pyogenes + Coccus Facultative Anaerobe 
Enterobacteriacea - Bacillus Microaerophile/Anaerobe 
Lactobacillus sp. + Bacillus Microaerophile/Anaerobe 
 
 
The Gram-stain is commonly used as the starting point in classification and 
identification of bacterial samples.34-36  It is a differential staining technique, which 
distinguishes between Gram-positive and Gram-negative specimens based upon 
structural differences in the cell walls.  Gram-positive bacteria have more disaccharides 
and amino acids which form a thicker peptidoglycan layer and stain purple, while Gram-
negative bacteria have a lipopolysaccharide layer which consists of lipids and 




determining the morphology or shape of a specimen as well.  The morphology of a 
bacterium is used in further classification and identification.  There are three categories: 
coccus specimens who are spherical, bacillus specimens who are rod-shaped, and 
spiral specimens.  
Bacteria are classified into five categories based upon requirement for and 
tolerance of atmospheric oxygen.34-36  Aerobic species are those which require 
abundant oxygen for metabolic processes and growth, while microaerophilic species 
require only a finite amount of oxygen and can be metabolically hindered or even killed 
by excessive amounts.  Facultative anaerobes prefer oxygenated environments for 
aerobic respiration, but are also capable of cellular respiration and fermentation under 
limited oxygen or anaerobic conditions.  Aerotolerant anaerobic species are 
fermentative and prefer oxygen-poor environments, but can tolerate the presence of 
oxygen, while obligate anaerobic species require the absence of oxygen.34,36  A 
depiction of oxygen requirements can be seen in Figure 1.34  Though bacteria from all 
five categories can be found in the human body, the oxygen content of the GI region is 
strictly limited or absent.  Therefore, the bacteria of interest for the purposes of this 




Figure 1 – Determination of Oxygen Requirements 
 
 
Three of the bacterial species discussed in Table 4 were chosen for analysis and 
include Escherichia coli (E. coli), Bacteroides fragilis (B. fragilis), and Clostridium 
perfringens (C. perfringens).  E. coli was chosen because it is commonly used in 
microbial research.  It is also a facultative anaerobic species highly concentrated in the 
human gastrointestinal tract.  Since the oxygen concentration is severely limited in the 
ileum and colon, the two obligate anaerobic species B. fragilis and C. perfringens were 
also chosen for observation in this research.  Effects of these bacterial specimens on 
the targeted drugs of abuse were investigated.  Results are discussed in Chapter 4. 
Postmortem, the populations of GI microflora are capable of otherwise inhibited 
transmigration.37  The body’s protective mechanisms both physical (membranes) and 
chemical (pH conditions) are compromised.  Bacteria are therefore no longer limited to 
their native habitats within the body, and are allowed access to areas that were 










Melvin et al. conducted a series of experiments using a combination of culturing 
techniques and scanning electron microscopy (SEM) to evaluate bacterial 
transmigration.37  In these experiments, a Carworth Farms No. 1 (CF-1) mouse was 
decapitated and the small intestine removed.  The intestine was divided into three 
sections.  The first section, the “control”, was immediately placed in a cold solution of 
2.5% buffered glutaraldehyde, and was used to assess tissue and environmental 
conditions of the sample immediately postmortem.  The middle section of the small 
intestine was cauterized and stored in solutions of phosphate-buffered saline.  The third 
section was used to evaluate the types of endogenous microbial organisms present via 
culturing techniques.  
The preparations were incubated at 4°C, 25°C, and 37°C to ascertain the effect 
of temperature on the rate of bacterial transmigration.  Samples of the gut were taken at 
intervals over a 72 hour period for each temperature study.  Fixed tissue samples of the 
gut were dehydrated in ethanol, dried, coated with gold, and examined with the SEM.  
Aliquots of the saline solution containing the middle section of the small intestine were 
taken at the same intervals for culturing.  
SEM analysis revealed that microbes migrated to the surface of the gut tissue 
within 2-3 hours at 37°C.  Appearances were delayed to 5-6 hours when incubated at 
25°C and 72 hours at 4°C.  Culture analysis demonstrated that rate of migration also 
depended upon the type microbial organism.  For example, Staphylococcus species 
were some of the first organisms cultured, regardless of temperature.  The authors 




to these species.  Fungi, coliforms, and facultative anaerobic species were cultured in 
later samples.  
Table 5 was adapted from the results of Melvin et al.37  This study indicated that 
many of the bacteria endogenous to the human intestine would be capable of 
transmigration within 72 hours postmortem, regardless of temperature.  
 









4°C 66-88 Hours 68-72 Hours >72 Hours 
25°C 5-6 Hours 8-10 Hours 12-16 Hours 




2.3.0 Bacterial Selection 
 
 
E. coli, B. fragilis, and C. perfringens were all classified as Biosafety Level 2 
(BSL-2) organisms.38  BSL-2 specimens are those which act as a potentially moderate 
threat to both the environment as well as personnel.39  Each of the organisms was 
specifically chosen due to human origin, and were ordered from the American Type 






2.3.1 Bacterial Characteristics 
 





Organism Escherichia coli (Migula) Castellani and Chalmers 
Designation B7 
Isolation Feces (Human) 
Biosafety Level BSL-2 
Antigenic Properties Serotype O86a:K61 
 
 
E. coli is a Gram-negative, rod shaped bacterium.38  It can be seen in various 
arrangements including singles, pairs, and short chains.  Size ranges between 0.5 μm in 
width and 1.0-3.0 μm in length.  A Gram stain of E.coli can be seen in Figure 2.  
Colonies are opaque gray/white while broth specimens are generally turbid with 
sediment.  E. coli can act as an anaerobic microbe as well as a facultative anaerobe.  
Possible growth temperatures range from 10-45°C, optimally between 30-37°C.  
 
Figure 2 – Gram Stain of E. coli 






B. fragilis is a Gram-negative, rod shaped bacterium commonly seen in singles or 
pairs.38  Size ranges between 0.5μm in width and 1.0-3.0μm in length.  Colonies tend to 
be small, gray, and irregular, and broth specimens are turbid.  B. fragilis is an anaerobic 
species with optimal growth at 37°C.  Table 7 shows characteristic of the B. fragilis 
specimen selected from the ATCC.38 
 





Organism Bacteroides fragilis (Veillon and Zuber) Castellani and Chalmers 
Designation 2044; [CDC 1261; M-488] 
Isolation Blood 
Biosafety Level BSL-2 
 
 
C. perfringens is a Gram-positive, rod shaped bacterium commonly seen in 
singles or pairs.38  Size ranges between 1.0-1.5 μm in width and 4.0-8.0 μm in length.  
Colonies are circular and slightly raised with an opaque center.  Broth specimens are 
usually turbid with sediment.  C. perfringens is an encapsulated and spore forming 
anaerobic species.  Growth is possible up to 50°C with optimal growth between 35-
37°C.  Table 8 shows the C. perfringens specimen chosen from the ATCC catalog.38 
 





Organism Clostridium perfringens (Veillon and Zuber) Hauduroy et al. 
Designation 43F4 
Isolation Bile (Human) 






2.4.0 Media Selection 
 
 
Several types of nutrient media were evaluated.  Components and conditions for 
M9 Medium (M9M) and tryptic soy medium (TS) were described in Table 9.38,40  
Components and conditions of RCM were previously discussed in Table 2.  Information 
about M9 salts, modified Wolin salts, and M9M were obtained from Melissa Dixon at 
Edgewood Chemical Biological Center.41 
 











 64.0 g Na2HPO4•7H2O 
 15.0 g KH2PO4 
 2.5 g NaCl  
 5.0 g NH4Cl DI H2O 
 
 






Modified Wolin Salts 
 3.0 g Nitrilotriacetic Acid 
 6.0 g MgSO4•7H2O 
 1.0 g NaCl 
 1.0 g MnSO4•H2O 
 0.50 g FeSO4•7H2O 
 0.10 g CaCl2•2H2O 
 0.10 g CoCl2•6H2O 
 0.10 g ZnSO4•7H2O 
 0.020 g H3BO3 
 0.010 g NaMoO •2H2O 










 200.0 mL M9 Salts 
 2.0 mL 1M MgSO4 
 0.10 mL 1M CaCl2 
 10.0 mL Modified Wolin Salts 
 
 




 17.0 g Tryptone 
 3.0 g Soytone 
 2.5 g Glucose  
 5.0 g NaCl 
 2.5 g K2HPO4 
 15.0 g Agar for TS Agar 
 
Adjust to 1.0 L 
 
Autoclave @121°C  




 M9M was prepared and then filtered to sterilize.  The broth of RCM and TS were 
prepared and autoclaved for sterilization.  A tube containing 10 mL of broth was 
inoculated with either E. coli, B. fragilis, or C. perfringens.  This was performed for all 
broth and bacteria combinations.  The tubes were incubated for 24 hours at 37°C under 
anaerobic conditions.  None of the bacterial species demonstrated growth in M9M.  This 
was attributed to the fact that M9M is a limited nutrient medium.  Bacteria require 
sources of carbon and nitrogen for growth, which are absent in M9M.  However, this 
medium would be ideal for sole source studies. 
E. coli demonstrated growth in TSB as evidenced by the cloudy nature of the 
broth post-incubation.  However, the tubes inoculated with B. fragilis and C. perfringens 
remained the clear yellowish-brown of freshly sterilized TSB.  This indicated bacterial 
growth for these species was not supported by TSB, making it a poor choice for 
experimental medium.  RCM supported and promoted growth of all three species and 
was therefore selected as the matrix for all of the experimental procedures. 
 
2.5.0 Certificates and Training 
 
 
Specific certifications and training were required for those handling or working 
with BSL-2 agents as well as for the laboratory itself.39  WVU required approval and 
clearance from the Director of Biological Safety for research involving biohazards.  WVU 
also required biosafety training through the Collaborative Institutional Training Initiative 
(CITI) program, which offered a Biosafety and Biosecurity (BSS) course.42  In addition, 
The Centers for Disease Control and Prevention (CDC) also recommended a 




Edgewood Chemical Biological Center (ECBC), a facility under the United States 
Army Research, Development and Engineering Command (RDECOM) required 
completion of the Effective Engineering Controls for Biological and Chemical Operations 
training set as well as the ECBC Visitor Risk Assessment for Chemical and Biological 
Non-Surety Laboratories.  The training requirements were fulfilled prior to 
commencement of the dissertation research. 
The experimental research was performed in the research labs of Dr. Suzanne 
Bell at West Virginia University as well as the facilities of Edgewood Chemical and 
Biological Center on the Aberdeen Proving Ground under Dr. Frederic Berg, Dr. Steve 
Harvey, and Melissa Dixon.  All of these facilities obtained the necessary permissions 
for the BSL-2 human specimen and bacterial work.  
 
2.6.0 Anaerobic Conditions 
 
 
Growth conditions and requirements for the anaerobes are specific.  Therefore, 
methods were developed to ensure optimal growth for each species.  Coy Laboratory 
Products, Inc. specializes in various types of anaerobic chambers.44  The Vinyl 
Anaerobic Chamber is specifically designed to meet the needs for anaerobic 






Figure 3 – Coy Laboratory Products, Inc. Type A Vinyl Anaerobic Chamber 




All models are equipped with an airlock system, gas regulator, catalyst fan 
boxes, 2 stak-paks with catalyst, a gas leak detector, and a plug strip for electronics 
(Coy Laboratory Products).  The Type A Chamber with automatic airlock and an 
incubator was chosen for this set of research experiments.  A schematic of the chamber 










Coy’s airlock and chamber systems require a combination of two gases.  A 
background gas, N2, was used to purge most of the oxygen out of the system through 
the vacuum pump and to inflate the chamber.  The second gas was a mixture of 95% N2 
and 5% of H2.  The H2 combined with O2 molecules within the chamber to form H2O 
molecules.  The stat-pak in each catalyst fan box contained a palladium catalyst which 
facilitated this reaction, and were switched out every 24 hours and dried in a laboratory 
oven to remove water and ensure optimal performance. 
The vinyl chamber offered several advantages over the aluminum and polymer 
versions.  The vinyl chamber required less combination gas consumption and anaerobic 
conditions were easier to maintain because of the ability of the walls to expand and 



















2.7.0 Frozen Stock Culture (3 Days) 
 
 
Prior to use, the ATCC cultures were stored at manufacturer recommended 
temperature, -80°C.  To ensure an adequate supply of bacteria for experimental 
procedures, a set of 10 stock cultures was prepared for each of the three species.  On 
day one, the plastic vial containing the lyophilized bacterial sample was removed from 
the protective packaging and placed in the anaerobic chamber.  A 1mL aliquot of sterile 
water was added to the vial.  Contents were vortexed and then transferred to a sterile 
BD Falcon™ tube (15 mL) containing 10 mL of RCM and incubated at 37°C.  This was 
repeated for all three bacterial specimens.  After 48 hours of incubation, tubes were 
removed from the incubator and examined for growth.  All three samples produced 
turbid cultures with a layer of bubbles as well as what appeared to be a gelatinous 
mixture that was present in all of the tubes.  This was identified as a small amount of 
agar, a component of RCM, which provided support to the anaerobic cultures.  It 
solidified to a slight extent during incubation.  After the samples were vortexed, the 
gelatinous portion mixed back in with the RCM broth.   
A 500 uL aliquot of 15% sterile glycerol in water was transferred into 10 small 
Eppendorf tubes per bacterial species.  The RCM culture tubes were removed from the 
incubator and vortexed for 30 seconds.  A 500 uL aliquot of this solution was transferred 
into each of the glycerol-water tubes.  The tubes were then sealed, gently vortexed to 






2.8.0 Plate Count Procedure (5 Days) 
 
 
There are many different methods used in the enumeration of bacteria or other 
microorganisms in a sample.  Direct microscope counts, electronic cell counters, and 
spectrophotometric analysis are all commonly used.34, 36  However, while these methods 
are capable of approximating the number of organisms within a sample, they offer one 
major disadvantage.  They are programmed to count the number of living, viable cells 
as well as any dead cells within the sample.36  For this set of experiments, it was 
important to only approximate the number of viable cells within the sample since these 
are the ones capable of metabolism.  Therefore, the serial dilution-agar plate method 
was used to estimate the number of viable bacteria within a sample following a given 
set of experimental conditions.  This method was applied to each of the target bacterial 
species using RCM agar plates and RCM broth.  
The plate count procedure required five consecutive days to complete.  A 














Figure 5 – Plate Count Procedure 
 
2.8.1 Plate Count Procedure Day 1 
 
On Day 1, streak plates for E. coli, B. fragilis, and C. perfringens were prepared 
from the frozen stock cultures.  The RCM agar plates were removed from the 
refrigerator and placed in the incubator set at 37°C for 15 minutes to remove the chill.  
One tube of frozen stock culture per species was moved from the -80°C freezer and 
placed in the anaerobic chamber.  An inoculation loop was dipped into the frozen stock 
culture and the agar plate was streaked using the standard streak plate procedure for 
isolated colonies.  Plates were incubated upside down at 37°C for 24 hours under 
anaerobic conditions.  Incubating plates upside down ensured that colony formation and 
growth were not interrupted by condensation that often forms on the lids of the plates 
during incubation.   In addition, four test tubes per specimen, each containing 10 mL of 
Day 1 
• Streak plate for each specimen; Incubated 
• 4-10 mL tubes of RCM per specimen; Autoclaved 
Day 2 
• 1 RCM tube inoculated with single specimen; 
Incubated 
Day 3 
• 3 fresh RCM tubes each inoculated with 250 µL of 
broth culture; Incubated 
• 27-9 mL tubes of DI water, Autoclaved 




• 9 Serial dilutions in DI water per tube of RCM 
• Spread plate 
 
Day 5  




RCM broth were autoclaved at 121°C for 15 minutes.  After sterilization, the tubes were 
stored on the bench top at room temperature until they were needed in Day 2 and Day 
3.  
2.8.2 Plate Count Procedure Day 2  
 
On Day 2, plates were examined for colony growth.  The E. coli plate was full of 
small, isolated, circular colonies.  However, the B. fragilis and C. perfringens plates 
were blank and looked as though they had not been previously streaked.  An ATCC 
representative suggested that the anaerobic specimens can often require 24-48 hours 
for colony formation, so those plates were returned to the incubator for another 24 hours 
at 37°C.  An isolated colony of E. coli was transferred to a test tube of RCM.  This tube 
was incubated at 37°C for 24 hours under anaerobic conditions.  
2.8.3 Plate Count Procedure Day 3 
 
On Day 3, the agar plates of B. fragilis and C. perfringens were again examined 
for colony formation.  Plates were still free and clear.  Most likely the RCM plates 
contained dissolved oxygen content that inhibited growth for the anaerobic species.  
Pre-reduced agar can be purchased from a microbiology supplies company, however 
these plates were quite expensive and there was not adequate funding at the time to 
support the purchase.  Therefore the plate count procedure was continued solely for the 
E. coli specimen. 
Since the drug samples used in later experiments (Chapter 4) were dosed from 
an inoculated broth media, it was important to determine the approximate number of 
viable bacteria administered under experimental conditions.  The E. coli test tube from 




density (OD) was recorded using a spectrophotometer set at 600 nm.  This served as a 
numerical value for sample turbidity and allowed the amount of bacterial growth 
between samples to be compared.  Three of the remaining tubes of RCM broth were 
inoculated with 250 μL of E. coli broth for replicate bacterial enumeration analysis. 
Samples were incubated at 37°C for 24 hours under anaerobic conditions.  After the 
tubes were incubated, the supplies for the dilutions and plating for Day 4 were prepared.  
9 mL of DI water was measured into 54 test tubes.   
2.8.4 Plate Count Procedure Day 4 
 
On Day 4, 3 sets of serial dilutions were prepared.  Each inoculated test tube 
from Day 3 served as Tube #1 for each Dilution Set.  A test tube rack was set up with 
the culture tube in position #1, followed by 9-9 mL tubes of sterile water labeled #2 - 
#10. Tube #1 was vortexed for 10 seconds and then a 1mL aliquot from Tube #1 was 
transferred by sterile pipet into Tube #2.  After the transfer, the tip was discarded and 
replaced with a new, sterile tip.  This was done to ensure that there was no carryover 
between dilutions.  In similar fashion, Tube #2 was thoroughly mixed and then 1mL of 
this solution was transferred into Tube #3.  This process was repeated until all of the 
dilutions were completed. This serial dilution method was applied to all 3 of the 
anaerobic E.coli cultures from Day 3.  
A pour plate method was originally attempted in the viable cell plate counts.  
After making the dilution sets, 1 mL from each serial dilution tube was transferred to a 
sterile petri dish.  Fresh RCM agar was autoclaved and then cooled to approximately 
55°C.  The melted agar was poured over the top of the 1 mL aliquot of dilution sample.  




within the agar.  The plates were incubated at 37°C for 24 hours under anaerobic 
conditions.   
There were several problems associated with this particular plate count method.  
As the agar cooled to the requisite 55°C, the solution became clouded with solidifying 
agar aggregates.  This created a problem as the plates were poured because large 
aggregations of agar would occasionally fall into the petri dishes.  Not only did these 
solids prevent desirable mixing of the aliquot sample with the agar, they also caused 
some of the aliquot to be displaced out of the petri dish.  This could affect the accuracy 
of the plate count method.   
In addition, bubbles and foam formed within the agar solution as it cooled.  These 
were transferred to pour plates along with the agar and made it difficult to distinguish 
viable cell growth from the set bubbles and foam.  This too would have had an impact 
on the accuracy of the plate count.  Finally, many bacteria display inhibited growth at 
higher temperature.  The optimal growth of Escherichia coli occurs at 37°C.  Growth is 
significantly hindered at temperatures greater than 45°C because the elevated heat 
reduces the number of viable cells.  Therefore, the raised agar temperature had the 
potential to kill some of the viable cells, which likewise would have affected the 
accuracy of the plate count.  Thus, the spread plate method was chosen to be a better 
choice with regards to the accuracy of the plate count results. 
To optimize the spread plate method, the amount of sample transferred onto the 
surface of the plate had to be determined.  Aliquots of 1 mL and 100 μL produced large 
landscapes of bacteria that coated the entire surface of the agar plate.  No single 




μL, 5 μL, and 2.5 μL were plated.  While 50 μL and 25 μL still produced surface growth 
(lawn) over the entirety of the plate, a smattering of single colonies was observed with 
the 10 μL, 5 μL, and 2.5 μL aliquots.  A new set of serial dilutions was performed and a 
10 μL aliquot of each was plated and incubated.  Plates were counted using the 
Advanced QCount Automated Colony Counter.  The majority of counts were within the 
30-300 count required for accurate viable bacterial estimation.  Therefore, the 10 μL 
aliquot was chosen for future spread plating of E. coli.  
The entire process was repeated from Day 1 to Day 4 for the E.coli sample under 
anaerobic as well as aerobic conditions for comparison.  On Day 4, after the dilutions 
were prepared, the contents of Tube #3 (102 dilution) were mixed thoroughly.  A 10 μL 
aliquot was transferred from Tube #3 onto the surface of an RCM plate labeled 102.  
The plate was placed on a petri dish turn table and the 10 μL aliquot distributed using a 
plate spreader.  This was done to ensure the agar surface was coated as evenly as 
possible.  This method was applied to each of the remaining Tube #4 - Tube#10 and 
agar plates labeled 103 through 109 to complete Dilution Set #1.  This method was 
completed for the remaining dilution sets, and plates were incubated at 37°C for 24 























2.8.5 Plate Count Procedure Day 5 
 
On Day 5, the colonies on the plates were counted using an Advanced QCount® 
Automated Colony Counter.  The system utilizes the patented ColorCount™ technology, 
which is based on principles of color recognition.  A lighted surface underneath the plate 
and adjustable background plates allow the user to achieve optimal resolution and 
achieve the most accurate plate count.   
The plates were retrieved from their respective incubation chambers, and the 




































































plate was placed on the viewing surface agar-side down.  The area multiplier was 
adjusted to 10% so as to include colonies that formed near the outer edges of the agar.  
Shutter speed was set to 1/250, while the size of the colonies adjusted to 0.2-20 mm. 
Plates containing fewer than 30 colonies were considered too few to count 
(TFTC) while plates containing more than 300 colonies were considered too numerous 
to count (TNTC).  The number of colonies was recorded for each plate using these 
specifications.  Table 10 summarized the plate count results for E. coli under aerobic 
conditions in RCM while Table 11 summarized results under anaerobic conditions. 
 









102 TNTC TNTC TNTC 
103 TNTC TNTC TNTC 
104 TNTC TNTC TNTC 
105 63 143 96 
106 34 29 69 
107 TFTC TFTC TFTC 
108 TFTC TFTC TFTC 
109 TFTC TFTC TFTC 
 
 









102 TNTC TNTC TNTC 
103 TNTC TNTC TNTC 
104 58 41 31 
105 39 35 33 
106 TFTC TFTC TFTC 
107 TFTC TFTC TFTC 
108 TFTC TFTC TFTC 




To calculate the approximate number of colony forming units (CFUs) in each 
sample, the appropriate dilution factor was applied to the colony number count.  In 
Anaerobic Plate Count for E. coli the 104 plate contained 58 colonies.  The calculation 
was performed using Equation 8. 
 
# Colonies = 58 
Dilution Factor = 104 
Volume of Dilution = 0.010 mL 
 
 
Equation 8 – Determination of Colony Forming Units 
 
     
                          
                 
 
   
  
    
 
 
Therefore, in this particular example,  
 
     
      
       
 
         
  
                
 
 
Only plates that contained between 30-300 colonies were included in the analysis.  The 
aerobic CFU/mL data was reported in Table 12, and anaerobic CFU/mL data in Table 
13. 
 




Individual Plate Counts (CFU/mL) 
105 6.3 x108 1.4 x109 9.6 x108 
106 3.4 x109 2.9 x109 6.9 x109 
Set Average 2.0 x109 2.2 x109 3.9 x109 










Individual Plate Counts (CFU/mL) 
104 5.8 x107 4.1 x107 3.1 x107 
105 3.9 x108 3.5 x108 3.3 x108 
Set Average 2.2 x108 2.0 x108 1.8 x108 
Overall Average 2.0x108 
 
As expected, the CFU/mL was greater for the aerobic preparations than the 
anaerobic preparations.  This was due to the fact that E. coli, a facultative anaerobic 
species, grew best under aerobic conditions (average OD = 0.770), but was also 
capable of growth under limited oxygen or anaerobic conditions to a lesser extent 
(average OD = 0.664).  These CFU/mL counts were near the approximate ranges of 
viable populations found in the human digestive tract as reported by the NIH, 
specifically the ileum (105 - 108) and colon (1010 - 1012).45 
 
 
2.9.0 Cellular Lysis 
 
2.9.1 Chemical Lysis  
Several methods of cellular lysis were considered during method development.  
Bug Buster® Protein Extraction Reagent by Novagen® is a type of chemical lysis 
solution that chemically disrupts the cellular structure of E. coli to release proteins.  The 
solution consists of a mixture of Tris-buffer and detergents that perforate the cell wall.  
This type of lysis was eliminated because RCM is a complex matrix, and addition of the 
lysis solution would further complicate the extraction and analysis of the target 





2.9.2 Microfluidizer  
 The microfluidizer is a type of homogenization instrument used to perform 
mechanical lysis.  The sample is driven into the interaction chamber where it encounters 
a series of microchannels.  High velocity flow of the sample creates high shear which 
acts in combination with impact forces to disrupt the cellular structure.   
A simple study was conducted using a Microfluidics M-110P to determine 
potential effects of microfluidization on sample analysis.  This instrument is depicted in 
Figure 7. 
 




A vial with lid was weighed empty, and then weighed again after addition of 5 mL 
of water.  The water sample in each vial was passed through the microfluidizer three 
times, and mass recorded after each pass.  The purpose of this experiment was to 




sample retrieval from the system.  The change in mass between runs was designed to 
identify changes in sample volume.  The microfluidizer data is summarized in Table 14. 
 




Empty Vial + Lid (g) 
 







1 6.40 11.33 11.38 11.32 11.26 
2 6.38 11.27 11.19 11.23 11.20 
3 6.40 11.35 11.48 11.43 11.49 
4 6.51 11.50 11.42 11.40 11.40 
5 6.41 11.30 11.20 10.88 11.04 
6 6.41 11.25 11.20 11.14 11.08 
7 6.41 11.36 11.39 11.44 11.29 
8 6.39 11.32 11.40 11.39 11.44 
9 6.41 11.37 11.34 11.23 11.15 
10 6.43 11.38 11.51 11.56 11.45 
 
 
Averages of the microfluidizer analyses were taken and then subtracted from the 
mass of vial, lid, and 5 mL of water.  The average volume difference was determined to 
be approximately 0.03 g ± 0.13 g.  These results are detailed in Table 15.  At room 
temperature, the density of water is approximately 1 g/mL.  Sample lysis by 
microfluidizer therefore resulted in an average of 30 µL (± 130 µL) increase in sample 
volume.  This would have affected the concentration of samples prior to LC-MS/MS 
analysis, which would have provided for inaccurate quantitation.  In addition, there was 
no way to guarantee proper flushing of the system between samples which could lead 











5mL DI H2O (g) 
 
Micro Average (g) 
 
Difference (g) 
1 4.93 4.92 +0.01 
2 4.89 4.83 +0.06 
3 4.95 5.07 -0.12 
4 4.99 4.90 +0.09 
5 4.89 4.63 +0.26 
6 4.84 4.73 +0.11 
7 4.95 4.96 -0.01 
8 4.93 5.02 -0.09 
9 4.96 4.83 +0.13 
10 4.95 5.08 -0.13 
 
2.9.3 Sonication 
 Sonication is another technique used in cellular lysis.  Three samples containing 
the benzodiazepine compounds and metabolites were prepared at 100 ng/mL and 
quantified via LC-MS/MS.  After analysis, the samples were sonicated for 10 minutes 
and then reanalyzed.  Post-sonication samples exhibited a concentration decrease for 
all analytes and metabolites, ranging from -3.6 to -6.2 ng/mL.  Because of the extent of 
concentration decrease, sonication was likewise ruled out as a method of cellular lysis 
for this research.  Analysis was performed directly on bacterial samples without cellular 





Chapter 3: Method Validation - Simultaneous Quantitation of 
Diazepam, Flunitrazepam, and Metabolites in Reinforced 







Analytical and forensic toxicology revolve around the detection, identification, and 
quantitation of compounds, particularly alcohol, pharmaceuticals, drugs of abuse, and 
other toxic or lethal substances.  There are many benzodiazepine methods available for 
common matrices such as blood46-48, plasma49, hair50, 51, and urine51-53, but these 
matrices do not provide all of the nutrients required to support the development and 
proliferation of bacterial species.  A medium like RCM, which was discussed in Table 2, 
however, provides the nutrients required to promote bacterial growth and therefore 
metabolism.  Diazepam (DZ) and flunitrazepam (FLU) were chosen as the analytes of 
interest because the human metabolites have been previously determined and chemical 
standards were commercially available.   
As detailed in Chapter 1, several studies have demonstrated that bacteria are 
capable of metabolizing complex chemical substances including drugs of abuse.  But, 
before the metabolic effects of GI bacteria on DZ and FLU could be investigated and 
compared to those of human metabolism, a method for the analysis and quantitation of 
these benzodiazepines and their metabolites in RCM needed to be developed.  To 
perform these tasks with reliability and certainty, the method likewise needed to be 




The presented method includes development and validation of a novel LC-
MS/MS method for the detection, identification, and quantitation of DZ, FLU, and their 
respective metabolites in RCM.  Application of this method was discussed in Chapter 4.  
DZ is classified as a Schedule IV benzodiazepine by the DEA, and acts as a 
central nervous system (CNS) depressant.54  In the medical industry it is most 
commonly known as Valium® and is usually administered in pill form, as a gel, or as an 
injection.  Street names include yellow V’s, blue V’s, foofoo’s, and Howards.  
It is most frequently prescribed as a sedative or tranquilizer, but can also be used 
in treatment of anxiety, convulsive disorders, and muscle spasms.  Health  effects 
include drowsiness, vertigo, vomiting, depressed respiration, elevated heart rate, coma, 
and death, particularly when the drug is abused.55  Known human metabolites of DZ 
include nordiazepam (NDZ), oxazepam (OX), and temazepam (TZ). 46,48,50-52,56  
FLU is also classified as a benzodiazepine and central nervous system 
depressant.  The DEA classifies it as a Schedule IV drug of abuse, however, 
possession and distribution are considered Schedule I offenses.  The manufacture, 
importation, sale, and usage are illegal in the United States.24,54,56  
By trade, FLU is labeled as Rohypnol®, and is commonly abused as a “date 
rape” drug.  On the street it may be referred to by a number of nicknames including 
circles, forget-me-pill, La Rocha, lunch money, Mexican Valium, Reynolds, roach, 
roofies, and wolfies to name just a few.24   
FLU can be taken in pill form, or crushed to be either snorted or ingested.  The 
powder is colorless, odorless, and tasteless when mixed into beverages and food, 




prevent resistance, often in cases of sexual assault.  Health effects include drowsiness, 
decreased anxiety, and impaired mental function.  Excessive doses can result in 
unconsciousness, anterograde amnesia, respiration suppression, and death.24  Human 
metabolites of FLU metabolites include 7-aminoflunitrazepam (7AM) and N-
desmethylflunitrazepam (NDES).47,48,51,53,57-59 47, 57,48, 51,53,58, 59  
 
 





Reference standards for DZ, NDZ, OX, TZ, FLU, 7AM, and NDES as 1.0 mg/mL 
and diazepam-d5 (DZ-d5), nordiazepam-d5 (NDZ-d5), oxazepam-d5 (OX-d5), 
temazepam-d5 (TZ-d5), flunitrazepam-d7 (FLU-d7), 7-aminoflunitrazepam-d7 (7AM-d7), 
and N-desmethylflunitrazepam-d4 (NDES-d4) as 100 µg/mL were purchased from 
Cerilliant® (Round Rock, TX).  Reagents and solvents consisted of 2-propanol (IPA) 
(Optima™ LC/MS) purchased from Fischer Scientific (Pittsburgh, PA), HPLC grade 
ethyl acetate (EA) from JT Baker® (Center Valley, PA), and formic acid (FA) eluent 
additive for LC-MS and LC-MS CHROMASOLV® acetonitrile (ACN) and methanol 
(MeOH) from Sigma-Aldrich® (St. Louis, MO).  The Strata-X-Drug N 100µ Polymer RP 
60 mg/3 mL cartridges used in sample preparation were obtained from Phenomenex® 
(Torrance, CA).  Compounds were separated using a narrow bore ZORBAX Eclipse 
XDB-C8 (2.1 mm x 150 mm x 5 µm) column affixed with a ZORBAX Eclipse XDB-C8 
(2.1 mm x 12.5 mm x 5 µm) guard cartridge from Agilent Technologies (Santa Clara, 





3.2.2 Sample Preparation 
 
Several working solutions were used to prepare the dilution samples required for 
method validation analyses.  All working solutions were prepared in water/methanol 
(60/40 v/v).  An internal standard working solution consisting of the seven deuterated 
analytes was prepared at 5000 ng/mL, and an analyte working standard consisting of 
the seven analytes of interest at 10,000 ng/mL (WS1).  Two additional working 
standards were prepared by dilution of WS1 at 1000 ng/mL (WS2), and 10 ng/mL 
(WS3).   
The matrix consisted of ten 100 mL aliquots of RCM (3.8 g RCM in 100 mL of DI 
water) that were pooled and then autoclaved at 121°C for 15 minutes.  Calibrators and 
sample dilutions were prepared in RCM from the appropriate working standard.  The 
final internal standard concentration in all 1 mL samples was 50 ng/mL.  
 
3.2.3 Sample Extraction 
 
An initial calibration curve was prepared from working solutions in buffer and 
plotted at 0.01, 0.05, 0.1, 0.5, 1, 5, 10, 50, 100, 250, and 500 ng/mL.  Calibration curves 
for each analyte in buffer can be seen in Appendix A.  Four different SPE methods were 
evaluated for recovery of DZ, FLU, and metabolites.  Reagents and solvents consisted 
of acetonitrile (ACN), ethyl acetate (EA), isopropyl alcohol (IPA), formic acid (FA), 
methanol (MeOH), and ammonium hydroxide (NH4OH).  Details of the methods are 
shown in Figures 8 and 9. 
Samples were extracted from RCM at three concentrations 0.05, 0.5, and 100 




retention time, accuracy, and ion ratios of analytes after extraction.  SPE method 1 was 
determined to be the best choice for extraction of all of the analytes of interest. 
 
Figure 8 – SPE Method 1&2 for Diazepam, Flunitrazepam, and Metabolites 
 
SPE 1 
Cartridge: Strata-X-Drug N 
      
 
SPE 2 
Cartridge: Strata-X-Drug B 
     
 
Figure 9 – SPE Method 3&4 for Diazepam, Flunitrazepam, and Metabolites 
 
SPE 3 
Cartridge: Strata-X-Drug N 
      
 
SPE 4 
Cartridge: Strata-X-Drug b 
      
 
Wash 




•EA/IPA (85/15 v/v) 
Wash 
•0.1% FA 
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Samples were extracted from RCM prior to analysis to minimize salts and other 
compounds that could interfere with or inhibit LC-MS/MS analysis.  The Strata-X-Drug N 
cartridge is a polymeric reversed phase cartridge designed for neutral drugs of abuse 
such as benzodiazepine compounds.  Solid phase extraction was performed on a 
vacuum manifold which can be seen in Figure 10. 
 




The manifold allowed for controlled extraction of up to 20 samples at a time.  
Following extraction, samples were dried on another manifold under ultrapure nitrogen 






Figure 11 – SPE Nitrogen Dry Down Manifold 
 
 
3.2.4 Instrumental Analysis 
 
Analysis was performed using an Agilent G6490 Triple Quadrupole LC/MS 
system equipped with iFunnel, G4226A HiP autosampler, G4220A binary pump, and 










2 µL of sample was injected into the system at a flow rate of 0.250 mL/minute.  
Mobile phases of water with 0.1% formic acid (A) and acetonitrile with 0.1% formic acid 
(B) were used in a gradient elution program of 40% B to 70% B over 6 minutes, holding 
at 70% B for 0.5 minutes, returning to original 40% B conditions over 0.1 minutes, and 
then a column equilibration of 1.4 minutes for a total run time of 8 minutes.  A post-run 
time of 2 minutes at 40% B was included between runs to ensure column equilibration 
before the next injection. 
Samples were ionized via Agilent Jet Stream electrospray ionization source (AJS 
ESI) in the positive mode.  Parameters were optimized with the Agilent MassHunter™ 
Source and iFunnel Optimizer software using a 100 ng/mL extracted sample of DZ, 
FLU, and their respective metabolites.  The range of values explored for each 
parameter, the increment by which conditions were changed, and the final optimized 




fragmentor (380 V), and cell acceleration (2 V).  Column temperature was maintained at 
37°C and autosampler at 20°C.   
 
Table 16 – Source and iFunnel Optimization for Diazepam, Flunitrazepam, and 









Capillary Voltage (V) 500-6000 200 3250 
Gas Temperature (°C) 120-290 20°C 265 
Gas Flow (L/min) 11-20 2 19 
Nebulizer (psi) 15-60 5 50 
Sheath Gas Temperature (°C) 150-400 20°C 350 
Sheath Gas Flow (L/min) 10-12 1 11 
 
MassHunter™ Optimizer software was used to determine the best multiple 
reaction monitoring (MRM) transitions for each analyte of interest as well as their 
corresponding deuterated standards.  The software provided up to four ion transitions 
for each target analytes and metabolite compound.  These tables can be seen in 
Appendix B.  All of the suggested ions were included in initial calibration.  However, the 
final quantifier and qualifier ions chosen for the method were those that demonstrated 
the greatest signal response while also maintaining stable ion ratio across the 
calibration range.    
MRM data was only acquired in a narrow window based upon the retention time 
of the analyte of interest.  Because some of the ions had similar ion transitions, the 
narrow range of acquisition increased the selectivity for each individual analytes.  
Samples were quantified by comparing the peak area response ratio of the target 




quantifier and (qualifier) MRM transitions, collision energy (CE), and ion ratio for each 
set of analytes and corresponding deuterated standards is summarized in Table 17. 
 




















DZ 5.13 285.1 153.9 25 66.3 
   (222.1) 25  
DZ-d5  290.1 198.1 29  
NDZ 3.92 271.1 140.1 21 69.2 
   (208.1) 25  
NDZ-d5  276.1 213.1 25  
OX 3.58 287.1 241.1 17 16.3 
   (162.9) 37  
OX-d5  292.1 246.1 17  
TZ 4.52 301.1 255.1 17 12.5 
   (176.9) 37  
TZ-d5  306.1 260.1 17  
FLU 4.51 314.1 268.1 21 46.4 
   (239.1) 33  
FLU-d7  322.2 276.1 25  
7AM 2.08 284.1 135.1 25 36.1 
   (226.2) 29  
7AM-d7  291.2 138.0 25  
NDES 3.69 300.1 253.9 21 43.7 
   (197.9) 37  




3.2.5 Method Validation 
 
Definitions and guidelines used in method validation were detailed in section 
1.5.0.  A full validation including a calibration model as well as interference studies, 
carryover effects, ionization suppression/ enhancement, recovery, bias, precision, limit 




of the method were evaluated.  The MRM output for the method was depicted in Figure 
13. 
 








3.3.1 Calibration Model 
 
Calibrators and quality control samples (QC) were prepared from the appropriate 
working solutions.  The final calibration model consisted of a 10-point calibration at 0.05, 
0.1, 0.5, 1, 5, 10, 50, 100, 250, and 500 ng/mL for the analytes of interest and 50 ng/mL 
for the deuterated standards extracted from RCM.  QCs were established at 1 (low) and 
100 ng/mL (high).  The calibration range, correlation coefficient, LOD and LOQ for each 
analyte can be seen in Table 18.  The calibration model was one of the most important 
features of method validation because subsequent analyses and quantitation were 











Table 18 – Calibration Range, Correlation, LOD, and LOQ for Diazepam, 










DZ 0.5-500 0.996 0.1 0.5 
NDZ 0.5-500 0.996 0.5 0.5 
OX 1.0-500 0.995 1.0 1.0 
TZ 0.5-500 0.996 0.5 0.5 
FLU 0.5-500 0.995 0.5 0.5 
7AM 0.1-500 0.996 0.1 0.1 
NDES 0.5-500 0.995 0.5 0.5 
 
 
3.3.2 Carryover Analysis 
 
Carryover analysis is a component of method validation advocated by SWGTOX.  
Because some LOQ values were as low as 0.1 ng/mL, carryover effects from high 
concentration samples posed a real threat to the accuracy of subsequent sample 
quantitation.  Carryover analysis was conducted at three concentrations including the 
highest calibration point of 500 ng/mL and two points at higher concentration: 700 
ng/mL and 900 ng/mL.  An extracted blank was injected after each sample to analyze 
carryover effects.   
Analysis of previously established identification criteria as well as agreement 
between experimental and theoretical concentrations indicated that the presented 
method was valid up to at least 900 ng/mL using the linear calibration model.  However, 
analysis of the blank injections proved that carryover was present for all target analytes 
at higher concentrations.  To counteract the effects of carryover, an extracted blank 







3.3.3 Interference Studies 
 
Interference studies were a component of method specificity as defined in 
section 1.5.3.  Ten samples of RCM matrix were pooled for validation interference 
studies.  Blank matrix samples were extracted and analyzed to identify matrix effects 
that could potentially affect analysis of the analytes of interest.  While there was some 
evidence of matrix effect based upon qualitative analysis, the established identification 
criteria of RT, peak shape, and ion ratios were not satisfied in blank specimens.   
Blank matrix was also spiked at 50 ng/mL for each deuterated standard to 
address possible interferences arising from similar fragmentation patterns of target 
analyte and corresponding deuterated standard as well as potential internal standard 
impurities.  The blank matrix samples containing deuterated standards likewise 
exhibited negligible interference based on the established identification criteria. 
 
3.3.4 Ionization Suppression/Enhancement and Recovery 
 
 Ionization suppression and enhancement studies were combined with ME, RE, 
and PE studies.  These were defined in Section 1.5.3.2 as components of method 
specificity.  Samples were prepared in duplicate and analyzed in triplicate for Sets A, B, 
and C at each concentration level.  Equations 1-3 as defined in Chapter 1 were used to 






Table 19 – Matrix Effects, Recovery, and Process Efficiency for Diazepam, 
Flunitrazepam, and Metabolites in RCM 
 
Analyte DZ ND OX TZ FLU 7AM NDES 
        
 High (100 ng/mL) 
ME (%) 99.1 97.1 97.2 97.6 96.9 98.8 97.9 
 RE (%) 95.3 97.0 96.4 94.7 95.4 97.8 95.5 
PE (%) 94.5 94.2 93.7 92.4 92.5 96.6 93.5 
        
 Low (1 ng/mL) 
ME (%) 92.2 118.9 87.6 93.8 91.1 94.8 99.3 
 RE (%) 119.5 117.8 117.9 118.2 114.6 116.5 117.6 
PE (%) 110.2 140.1 103.4 110.9 104.4 110.4 116.8 
 
Matrix effects ranged from 97-99% at high concentrations but demonstrated 
greater variation at lower concentrations from 91-119%.  At low concentration, all of the 
target analytes exhibited ionization suppression from interfering compounds in the 
matrix except for NDZ, which exhibited ionization enhancement.  The suppression and 
enhancement effects were likely due to compounds within the RCM matrix that co-
eluted with the target analytes thereby affecting the ionization efficiency. 
Recovery ranged from 95-98% at high concentration.  At low concentration, all of 
the analytes exhibited recoveries over 100%, ranging from 115-119%.  This indicated 
that samples spiked with analytes and deuterated standards prior to extraction (Set C) 
exhibited higher experimental concentrations than samples spiked after the extraction 
process (Set B).  This was likely due to matrix components that were not removed 
during SPE.  This explanation was supported by the ionization enhancement effects 
seen in % ME at low concentrations. 
Analytical recovery was representative of the effectiveness of the sample 




towards neutral drugs of abuse such as benzodiazepines.  The SPE method included 
an aqueous wash step with acetonitrile/water (20/80 v/v) which helped to remove much 
of the salt content of the media.  Samples were eluted with EA/IPA (85/15 v/v), which 
enhanced the separation of remaining polar compounds in the matrix from the analytes 
of interest.  Since the SPE method focused on removal of polar matrix components and 
salts, the recovery enhancement was likely due to nonpolar media components 
coeluting with the analytes of interest. 
PE compared the spiked samples that went through the full extraction method 
(C) to the samples prepared in neat buffer (A).  These values and ranged from 92-97% 
at high concentrations and 103-140% at lower concentrations.  PE can also be 
considered as the combined effects of ME x RE, which accounted for the greater range 
of variation, especially for NDZ which was more sensitive to matrix effects. 
 
3.3.5 Bias and Precision 
 
Bias and precision studies were studied at four representative concentrations 
0.500 (low), 1 (medium/low), 50 (medium), and 500 (high) ng/mL for DZ, NDZ, TZ, FLU, 
7AM, and NDES, and three concentrations 1 (low), 50 (intermediate), and 500 ng/mL 
(high) for OX.  Analysis was adjusted for OX because the LOD and LOQ values were 
higher than the other analytes at 1ng/mL.  Five samples were prepared and extracted 
for each concentration and analyzed in triplicate.   
The bias of the method was defined in Section 1.5.5 and calculated using 
Equation 5.  Generally, the higher concentration sample sets had the narrowest range 
of values, which became broader as the concentration decreased toward analyte LOQ.  




small changes in sample extraction and preparation as well as instrumental response 
had a greater effect on lower concentrations than higher concentrations, causing the 
range of values to broaden. 
Precision and repeatability of the method were determined using the same data 
set as bias analysis.  Precision was defined in Section 1.5.6 and calculated as within-
run precision via Equation 6.  Repeatability of the method was defined in Section 1.5.7 
and calculated as between–run precision using Equation 7.  The acceptable range for 
both bias and precision was ±20% and values were recorded in Table 20.  Both sets of 
precision values followed the same trend as that seen with bias with narrowest range of 






Table 20 – Bias, Within-Run and Between-Run %CV for Diazepam, Flunitrazepam, and 
Respective Metabolites in RCM  
 
Bias and Precision 
 
Analyte DZ ND OX TZ FLU 7AM NDES 
        
High (500 ng/mL) 
Bias -2.1 -3.6 -3.0 -2.0 -3.4 -2.5 -1.7 
Within-Run 1.8 2.3 1.8 2.0 2.6 1.5 2.3 
Between-Run 2.8 2.8 2.7 2.7 2.9 2.9 3.8 
        
        
Medium (50 ng/mL) 
Bias -3.6 -5.5 -9.9 -8.5 -10.5 -5.5 -8.1 
Within-Run 1.7 2.9 1.8 2.4 1.9 1.9 2.0 
Between-Run 2.8 3.6 2.1 3.4 2.7 2.5 3.4 
        
Medium/Low (1 ng/mL) 
Bias -8.9 1.3 -12.1 -17.6 -14.4 -8.0 -10.7 
Within-Run 4.4 4.4 11.3 5.0 5.2 2.1 5.5 
Between-Run 5.4 5.9 11.7 5.9 5.9 4.0 5.0 
        
Low (0.500 ng/mL) 
Bias -5.7 -6.8 NA -9.7 -13.1 -14.9 -4.5 
Within-Run 3.6 4.7 N/A 10.5 10.2 2.1 12.2 
Between-Run 4.6 6.0 N/A 8.1 6.6 4.0 9.5 
 
 
3.3.6 Dilution Integrity 
 
 To determine dilution integrity (Section 1.5.11), bias and precision studies were 
repeated for the diluted samples.  This was an important feature of method validation 
because biotransformation samples were spiked at 1000 ng/mL (Chapter 4).  Common 
dilution ratios of 1:2 for an 800 ng/mL sample and 1:5 for a 1000 ng/mL sample were 
examined.  Five samples per concentration level were prepared, extracted, and 
analyzed in triplicate.  Both sets of dilutions maintained the require identification criteria.  




ranged from 1.8-5.4% and between run precision from 2.1-3.9%.  Bias and precision 
data for the dilution samples was summarized in Table 21.  Future dilutions could be 
prepared at either 1:2 or 1:5 and maintain sample integrity.   
 
Table 21 – Dilution Integrity for 1:2 and 1:5 Sample Dilutions  
        
Dilution Integrity 
 
1:2 (800:400 ng/mL) 
Bias 0.55 6.7 2.7 -2.6 -1.9 -5.6 -6.9 
Within-Run 1.8 3.6 2.7 3.9 4.3 3.2 4.0 
Between-Run 2.1 2.2 2.7 2.4 3.1 2.2 2.6 
 
1:5 (1000:200 ng/mL) 
Bias 1.4 7.9 1.5 -3.3 -1.1 -3.4 -8.1 
Within-Run 4.4 3.2 4.8 5.4 3.8 4.0 3.3 
Between-Run 3.1 3.6 3.9 3.4 2.6 3.0 3.3 
 
 
3.3.7 LOD and LOQ 
 
The LOD and LOQ criteria are summarized in sections 1.5.8 and 1.5.9, 
respectively.  Values ranged from 0.100 to 1 ng/mL for DZ, FLU, and metabolites.  
Results were included in Table 18.  DZ and 7AM achieved the lowest LOD and LOQ 
values at 0.1 ng/mL.  However, while DZ achieved acceptable RT, peak shape, and ion 
ratios at 0.1 ng/mL which satisfied LOD requirements, the bias exceeded ± 20%.  LOQ 
requirements were fulfilled at 0.5 ng/mL for DZ.  The remaining analytes of interest 
achieved LOQ values ≤ 0.5 ng/mL with the exception of OX.   
OX samples were within the appropriate RT window and maintained good peak 
shape.  However, the ion ratio analysis prevented detection and quantitation limits from 
being confirmed with certainty at lower concentrations.  This was supported by data 




high concentration to 87.6% at low concentration, indicating that ionization suppression 
of OX was greater at low concentrations.   
Additionally, the % RE increased from 96.4% (high) to 117.9% (low).  This 
supported the inconsistent ion ratios seen in analysis of LOD and LOQ determination.  
The accuracy and bias of OX samples at low concentrations were within the acceptable 
± 20%.  However, the ion ratios at low concentrations increased.  Ion ratios were 
calculated as a ratio of response between qualitative ion: quantitative ion.  Increase in 
ion ratio indicated an increase in response of the 162.9 m/z transition in comparison to 
that of the 241.1 m/z transition.  This could have been indicative of a matrix component 




The FT and processed sample stability were both assessed as part of the 
method validation.  FT stability was conducted at two concentrations 500 ng/m (high) 










































At high concentration the acceptable range of ±20% was between 400-600 
ng/mL.  NDZ, OX, FLU, NDES exhibited a slight increase in response between FT1 and 
FT2 while the other compounds showed a decrease.  Since an extracted matrix blank 
was injected between each sample, these effects were not due to carryover.  The 
results were likely due to fluctuations in instrumental response.  All analyte 
concentrations decreased from FT2 to FT3, which was expected. However none of the 
compounds fell below 400 ng/mL, which indicated that samples would retain stability 
through 3 FT cycles at high concentration.  
The freeze-thaw cycle for 1 ng/mL samples was depicted in Figure 15.  At low 
concentration the acceptable range was between 0.8 and 1.2 ng/mL.  NDZ and NDES 
again displayed an increase in response between FT1 and FT2 while the other analytes 
decreased in concentration.  All analyte concentrations decreased between FT2 and 
FT3.  Unlike what was seen at high concentration, responses for OX, TZ, and FLU fell 
below 0.8 ng/mL.  For this method, it was therefore concluded that samples may 
undergo up to two FT cycles and still maintain stability criteria, but cannot be analyzed 










































The stability of processed samples was studied to address possible effects of 
large sample batches or instrumental malfunctions that would prevent samples from 
being analyzed immediately.  Stability studies were conducted at two concentrations 
500 ng/mL (high) and 0.500 ng/mL (low).  Two samples were prepared in RCM at each 
concentration, extracted, reconstituted, and analyzed in triplicate over 48 hours.  Eleven 
samples were run at time 0, 3, 6, 9, 12, 15, 18, 24, 30, 36, and 48 hours.  For high 
concentration, analyte response ranged from FLU at 477 ng/mL to OX at 563 ng/mL.  
The processed samples remained stable for at least 48 hours for all analytes of interest.  
Results can be seen in Figure 16.  
For low concentration samples at time 48 hours, responses ranged from 7AM at 
0.462 ng/mL and DZ at 0.534 ng/mL.  Results can be seen in Figure 17.  Based on the 
processed sample stability studies, all analytes of interest maintained stability for at 




















































































Robustness of the method was defined in Section 1.5.13 and determined by 
slight changes in the buffer composition and column temperature.  Samples were run at 
0.5, 5, 50, 250, and 500 ng/mL for each variable.  Buffer A for this benzodiazepine 
method consists of water with 0.1% formic acid.  The effect of changes in buffer 
composition was assessed by running a series of samples with buffers containing 
0.05%, 0.1%, and 0.15% formic acid.  Samples with the 0.05% and 0.1% formic acid 
buffer maintained identification criteria and experimental concentrations were within 
±20% for all concentration levels.   
The 0.15% formic acid samples maintained identification and accuracy criteria for 
5, 50, 250, and 500 ng/mL but ranged from 108-141% for the 0.5 ng/mL sample.  The 
same samples were used for the buffer composition studies, so this effect was not due 
to differences in sample preparation or extraction.  RT, peak shapes, and ion ratios all 
experienced more fluctuation with this buffer composition for all analytes.  Peak shapes 
at the lowest concentration of 0.5 ng/mL were no longer Gaussian which affected the 
accuracy of quantitation.   
Column temperature for the validated method was held at 37°C.  The effects of 
column temperature were analyzed at 30°C, 37°C, and 40°C.  Identification and 
accuracy criteria were met for DZ, OX, TZ, FLU, 7AM, and NDES for all concentration 
levels and temperatures.  The 0.5 ng/mL sample for OX at 40°C robustness study 
exceeded the ±20% theoretical concentration allotment at 134%.  However, the LOD 




quantified at 0.5 ng/mL with certainty using this method regardless of column 
temperature. 
In addition to buffer composition and column temperature, an alternate analyst 
prepared samples at the five concentration levels for analysis. Identification criteria were 





Validation of this method was essential for further studies on the 
biotransformation of drugs of abuse by bacteria grown in RCM.  This LC-MS/MS 
method was used to analyze and quantify the bacterial biotransformation phenomena 
presented in Chapter 4.  It will also be used to compare the bacterial products to those 





Chapter 4: Detection and Quantitation of Diazepam and 
Flunitrazepam Metabolites Produced by Anaerobic Bacterial 
Species in Reinforced Clostridial Medium using Liquid 






The ability of bacterial species to transform a variety of complex compounds has 
been well documented.  Some of these species are native to the human GI tract and 
may have the potential to cause biotransformations that affect the ratio of compound-to-
metabolite concentrations within the human body.  Investigation of these possibilities 
required optimization of bacterial growth conditions, a method of analyte extraction from 
the nutrient medium RCM, and an LC-MS/MS method for analysis and quantitation of 
experimental results.  Bacterial growth conditions and methods were optimized in 
Chapter 2 of this document, and the SPE and LC-MS/MS methods were developed and 
validated in Chapter 3.   
Chapter 4 is essentially the culmination and application of the previous work.  
Experiments focused on the effects of E. coli, B. fragilis, and C. perfringens on DZ, FLU, 
and their metabolites in RCM under anaerobic conditions.  DZ and FLU are 
benzodiazepine compounds of forensic importance and interest.  They were selected 
for biotransformation studies because the human metabolites have been previously 








4.2.0 Diazepam Metabolism 
 
 
Human metabolites of DZ include nordiazepam (NDZ), oxazepam (OX), and 
temazepam (TZ) and can be seen in Figure 17.46,48,50-52,56,60-62 46,48,50-52,56,50, 52, 60,61,62  
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4.3.0 Flunitrazepam Metabolism 
 
 
Human metabolites of FLU include 7-aminoflunitrazepam (7AM) and N-
desmethylflunitrazepam (NDES) and can be seen in Figure 18.47,48,51,53,57-59 47,48, 51,53,57-59  
The 3-hydroxyflunitrazepam metabolite was not included in analysis because it was not 
available at the time of method development and validation. 
 
Figure 19 – Human Metabolites of Flunitrazepam 




     
     
     
     






      
     






Escherichia coli (33985), Bacteroides fragilis (29771), and Clostridium 
perfringens (19574) were purchased from the American Type Culture Collection® 
(Manassas, VA).  BD Difco™ Reinforced Clostridial Medium and sterile 15 mL 
Flunitrazepam 
7-Aminoflunitrazepam N-Desmethylflunitrazepam 




polypropylene BD Falcon™ tubes were obtained from BD Diagnostic Systems (Sparks, 
MD).  The Vinyl Anaerobic Chamber (Type A) with automatic airlock and incubator 
produced by Coy Laboratory Products Inc was used for anaerobic incubation (Grass 
Lake, MI).  Reference standards were purchased from Cerilliant® (Round Rock, TX) as 
1.0 mg/mL for DZ and FLU.  All other materials used in extraction and LC-MS/MS 






 E.coli, B. fragilis, and C. perfringens required specific environmental growth 





The RCM was prepared according to manufacturer instructions by dissolving 38 
grams of dehydrated RCM in purified water.  The medium was autoclaved at 121°C for 
15 minutes.  RCM was transferred to the anaerobic chamber and stored with the cap 
loosened for 48 hours to promote evacuation of dissolved oxygen.  This was particularly 
important for growth of C. perfringens.  After evacuation, RCM was capped and stored 
at room temperature until further use. 
 
4.5.3 Bacterial Sample Preparation 
 
One of the frozen stock cultures described in Section 2.7.0 was removed from 




sterile 15 mL tube containing 10 mL of RCM and incubated with the lid loosened at 
37°C for 48 hours.  This process was repeated for all three bacterial species.   
Blanks and biotransformation samples were all prepared in 10 mL of RCM.  They 
were dosed with analyte and/or bacterial specimen as outlined in Table 22.  
Immediately after the samples were prepared, they were vortexed for 30 seconds, 
inverted 10 times, and vortexed for an additional 30 seconds to ensure thorough mixing.  
A 200 µL pre-incubation aliquot of each sample was transferred to an Eppendorf tube 
and transported out of the anaerobic chamber for analysis.  Samples were incubated 
with the lid loosened at 37°C for 48 hours. 
 













DZ Blank 1000 - - - - 
FLU Blank - 1000 - - - 
E. coli Blank - - 250 - - 
B. fragilis Blank - - - 250 - 
C. perfringens Blank - - - - 250 
Mixed Culture Blank - - 100 100 100 
DZ + E.coli 1000 - 250 - - 
DZ + B. fragilis 1000 - - 250 - 
DZ + C. perfringens 1000 - - - 250 
DZ + Mixed Culture 1000 - 100 100 100 
FLU + E.coli - 1000 250 - - 
FLU + B. fragilis - 1000 - 250 - 
FLU + C. perfringens - 1000 - - 250 
FLU + Mixed Culture - 1000 100 100 100 
 
 
The 200 µL pre-incubation aliquot (concentration 1000 ng/mL) was combined 
with 10 µL of internal standard working solution (5000 ng/mL) and 790 µL 
water/acetonitrile (60/40 v/v) buffer for a 1:5 dilution (Section 3.3.6).  Pre-incubation 




Post-incubation, samples were removed from the chamber after 48 hours, 
vortexed for 30 seconds, inverted 10 times, and vortexed for an additional 30 seconds 
to ensure uniform composition throughout.  The OD was measured for comparison to 
the values obtained during the plate count method.  Another 200 µL aliquot of each 
sample was extracted and analyzed as the post-incubation counterpart.  Instrumental 
parameters, MRM transitions, SPE, and the LC-MS/MS method of analysis are all 
described in Chapter 3. 
 
4.6.0 Results and Discussion 
 
 
Two sets of DZ and FLU biotransformation experiments were conducted while 
the LC-MS/MS method was being developed and validated.  Samples were prepared 
following the same guidelines as those described in Table 22 and stored in the freezer 
until they could be extracted and analyzed.  These sets of experiments were analyzed 
but both of them were rendered useless.   
In the first set, nearly all of the media samples inoculated for biotransformation 
studies failed to support bacterial growth.  E. coli was the only specimen to produce any 
sort of turbidity, as evidenced by the resultant OD values.  However, even these 
samples were barely distinguishable from the RCM blanks.  Purging RCM in the 
anaerobic chamber for 48 hours after sterilization eliminated this problem, and all of the 
bacterial species demonstrated prominent growth. 
The second set of samples was analyzed via LC-MS/MS.  However, there was 
no way to determine the original concentrations of the samples prior to incubation.  Any 




species.  Decrease in theoretical concentration could have been a result of incomplete 
dosing.  It could also have been due to unassisted degradation of the analyte under 
experimental conditions.  This dilemma was solved by implementing analysis of pre-
incubation as well as post-incubation aliquots of the samples. 
 
4.6.1 Bacterial Blanks 
 
A series of bacterial blanks were prepared with aliquots of E. coli, B. fragilis, C. 
perfringens, or a mixture of the three without analytes of interest.  None of the bacterial 
specimens produced interferences with the target analytes that satisfied identification 
and confirmation requirements of peak shape, retention time, ion ratio, and that were 
above the analyte LOQ. 
 
4.6.2 Diazepam Blanks 
 
 A series of analyte blanks was prepared in RCM and incubated alongside 
samples inoculated with bacteria.  Two blanks per analyte were spiked with either DZ or 
FLU and incubated at 37°C for 48 hours.  Samples were evaluated via OD 
measurement to ensure that the media remained clear and turbidity-free over the 
course of the experiments.  Pre- and post-incubation aliquots were extracted and 
analyzed via LC-MS/MS.  Analytes and metabolites were evaluated for acceptable peak 
shape, retention time, ion ratios, and S/N ≥ 3 for detection, and with bias and precision 
within ±20% for quantitation. 
Analysis of DZ Drug Blank 1 (Table 23) demonstrated an average change in 
concentration of -11.1 ± 3.2 ng/mL and DZ Drug Blank 2 (Table 24) an average 




pre- to post-incubation concentrations to account for the DZ conversion.  Standard 
deviations were determined at the 95% confidence interval.   
The RCM for both DZ blank samples maintained its clarity and did not exhibit any 
characteristics that would indicate bacterial presence.  The discrepancy in mass 
balance between pre- and post-incubation samples suggested that DZ must undergo a 
partial, unassisted degradation to a compound other than those found in normal human 
metabolism.  This was likely due to molecule instability when incubated at 37°C for 48 
hours.   
 
Table 23 – Pre- and Post-Incubation Analysis: Diazepam Drug Blank 1  
 Concentration (ng/mL) 
Sample DZ NDZ OX TZ 
Pre DZ Blank 1 165.3 ± 0.5 0.1 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
Post DZ Blank 1 154.2 ± 3.1 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
Δ Concentration Average -11.1 ± 3.2 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
 
Table 24 – Pre- and Post-Incubation Analysis: Diazepam Drug Blank 2  
 Concentration (ng/mL) 
Sample DZ NDZ OX TZ 
Pre DZ Blank 2 187.9 ± 2.6 0.1 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
Post DZ Blank 2 166.4 ± 1.2 0.0 ± 0.0 0.0 ± 0.0  0.0 ± 0.0 
Δ Concentration Average -21.4 ± 3.6 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
 
   
 A literature search of previously published research identified several possibilities 
for alternative metabolites including 4’-OH DZ (metabolite of DZ) and 4’-OH norezepam, 





Figure 20 – Alternative Metabolites of Diazepam and Nordiazepam 









   
   













   
   
   
   














 4.6.3 Effects of E.coli on DZ 
 
 RCM samples prepared for biotransformation studies were spiked with an 
analyte of interest at 1000 ng/mL as well as either E. coli, B. fragilis, C. perfringens, or a 
mixture of the three.  Each sample was prepared in duplicate and analyzed in triplicate.  
Diazepam 








Pre- and post-incubation aliquots were taken for analysis and the change in 
concentration results were calculated.   
The RCM in DZ biotransformation studies inoculated with E. coli demonstrated 
the marked turbidity indicative of prominent bacterial growth.  As discussed in Section 
2.8.0, a 250 µL aliquot of E. coli resulted in approximately 2.0 x 108 CFU/mL after 
anaerobic incubation, which was comparable to estimates of bacterial enumeration in 
the human ileum and colon.  The OD and turbidity of RCM supported that viable E. coli, 
those capable of growth, division, and metabolic activity, were present in the 
biotransformation study samples.   
Analysis of the effects of E. coli on DZ concentration demonstrated an average 
change in concentration of –28.1 ± 2.7 ng/mL in sample 1 and -40.0 ± 3.0 ng/mL in 
sample 2.  These results were summarized in Table 25 and Table 26, respectively. 
 
Table 25 – Pre- and Post-Incubation Analysis: Effects of E. coli on Diazepam 1 
 Concentration (ng/mL) 
Sample DZ NDZ OX TZ 
Pre E.coli 1 191.8 ± 2.1 0.1 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
Post E.coli 1 163.7 ± 1.5 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 







Table 26 – Pre- and Post-Incubation Analysis: Effects of E. coli on Diazepam 2 
 
 Concentration (ng/mL) 
Sample DZ NDZ OX TZ 
Pre E.coli 2 197.9 ± 1.6 0.1 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
Post E.coli 2 157.9 ± 1.7 0.0 ± 0.0 0.0 ± 0.7 0.0 ± 0.0 
Δ Concentration -40.0 ± 3.0 0.1 ± 0.0 0.4 ± 0.7 0.0 ± 0.0 
 
As seen in the drug blank samples, neither NDZ, OX, nor TZ registered a 
detectible or quantifiable increase from pre- to post-incubation concentrations.  In 
sample 2, instrumental response did indicate a decrease in ND concentration of 0.1 ± 
0.0 ng/mL, and an increase in OX concentration of 0.4 ± 0.7 ng/mL between pre- and 
post-incubation samples.  However, the ion ratios for NDZ and OX were not within the 
acceptable range of ± 20% as defined in Table 17.  The experimental values were also 
below the LOD and LOQ values established in the method validation (Section 3.3.7, 
Table 18) for both analytes.  Without fulfillment of these components along with RT and 
peak shape, an analyte cannot be detected or confirmed with certainty.  Therefore, the 
changes in concentration for NDZ and OX were insignificant. 
The average change in concentration between pre- and post-incubation DZ 
blanks ranged from -11.1 to -21.4 ng/mL while samples incubated with E. coli ranged 
from -28.1 to -40.0 ng/mL.  The discrepancies between blank and biotransformation 
study samples, though slight, indicated that there may be additional factors contributing 
to the transformation of DZ when incubated with E.coli.  While the majority of DZ 
disappearance could be attributed to the proposed unassisted degradation, the mass 
balance of the reaction suggested that DZ was being converted to a compound other 




possessed a specific enzyme or combination of enzymes that were capable of cleaving 
DZ to form some type of alternative minor metabolite.  
 
4.6.4 Effects of B. fragilis on DZ 
  
Turbidity in B. fragilis samples was comparable to that seen in the bacterial blank 
and E. coli biotransformation incubations.  Analysis of the effects of B. fragilis on DZ 
demonstrated an average change in DZ concentration between pre- and post-
incubation of -46.2 ± 2.2 ng/mL in sample 1 and -23.9 ± 3.5 ng/mL in sample 2.  These 
results were summarized in Table 27 and Table 28, respectively. 
 
Table 27 – Pre- and Post-Incubation Analysis: Effects of B. fragilis on Diazepam 1 
 Concentration (ng/mL) 
Sample DZ NDZ OX TZ 
Pre B. fragilis 1 179.7 ± 1.5 0.1 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
Post B. fragilis 1 133.5 ± 0.8 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
Δ Concentration -46.2 ± 2.2 -0.1 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
 
 
Table 28 – Pre- and Post-Incubation Analysis: Effects of B. fragilis on Diazepam 2 
 Concentration (ng/mL) 
Sample DZ NDZ OX TZ 
Pre B. fragilis 2 172.5 ± 3.3 0.1 ± 0.0 0.0 ± 0.1 0.0 ± 0.0 
Post B. fragilis 2 148.6 ± 0.9 0.1 ± 0.0  0.0 ± 0.0 0.0 ± 0.0 
Δ Concentration -23.9 ± 3.5 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
 
 In agreement with the analyte blank and biotransformation studies with E. coli, 
the mass balance of DZ was affected; however, NDZ, OX, nor TZ registered a response 
greater than their respective LOD or LOQ in incubations with B. fragilis.  As suggested 
with the E. coli studies, the majority of DZ disappearance could be attributed to the 




that observed in the analyte blanks.  This may have resulted from an enzymatic reaction 
utilized by B. fragilis to cleave DZ and produce an alternative metabolite.  It is unclear 
whether E.coli and B. fragilis employed the same enzyme to account for the 
discrepancy between the drug blank and bacterially inoculated samples or if the DZ 
cleavage was attributed to species-specific enzymes. 
The proposed alternative metabolites could be added to the LC-MS/MS method 
and monitored for changes between pre- and post-incubation analysis.  A kinetic study 
on the rate of disappearance of DZ might also provide valuable information that could 
aid in compound identification.  Additionally, analysis of the post-incubation sample via 
LC-MS/MS in full scan mode might offer some information about the m/z of the 
unidentified compound. 
 
4.6.5 Effects of C. perfringens on DZ 
  
The effects of C. perfringens on DZ produced marked turbidity and a 
concentration difference of -0.7 ± 2.7 ng/mL in sample 1 and -1.5 ± 1.0 ng/mL in sample 
2.  Results were summarized in Table 29 and Table 30.  
 
Table 29 – Pre- and Post-Incubation Analysis: Effects of C. perfringens on Diazepam 1 
 Concentration (ng/mL) 
Sample DZ NDZ OX TZ 
Pre C. perfringens 1 172.5 ± 1.5 0.1 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
Post C. perfringens 1 171.9 ± 1.3 0.1 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 






Table 30 – Pre- and Post-Incubation Analysis: Effects of C. perfringens on Diazepam 2 
 Concentration (ng/mL) 
Sample DZ NDZ OX TZ 
Pre C. perfringens 2 184.9 ± 0.5 0.1 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
Post C. perfringens 2 183.5 ± 0.5 0.1 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
Δ Concentration -1.5 ± 1.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
 
Similar to the studies performed on E. coli and B. fragilis, there were negligible 
changes in concentration detected for NDZ, OX, and TZ.  However, there was minimal 
change in DZ concentration as well.  These findings supported the theory that effects of 
E. coli and B. fragilis resulted in the discrepancies between DZ analyte blanks and their 
respective biotransformation studies.   
The small change in DZ concentration, however, is unique.  Disappearance of 
DZ concentration similar to that seen in the analyte blanks was expected.  However, this 
was not observed in the DZ samples inoculated with C. perfringens.  The concentration 
difference between pre- and post-incubation was small enough that it could potentially 
be explained by differences in instrumental response.  Because DZ experienced this 
uniquely minimal concentration loss, it is possible that introduction of C. perfringens or 
perhaps a bacterial secretion somehow stabilized the analyte and prevented conversion 
or degradation. 
4.6.6 Effects of a Mixed Culture on DZ 
  
The effects of joint incubation with E. coli, B. fragilis, and C. perfringens on DZ 
produced turbid samples with a concentration difference of -1.1 ± 1.8 ng/mL in sample 1 







Table 31 – Pre- and Post-Incubation Analysis: Effects of Mixed Culture on Diazepam 1 
 Concentration (ng/mL) 
Sample DZ NDZ OX TZ 
Pre Mixed Culture 1 140.0 ± 0.7 0.1 ± 0.0 0.0 ± 0.0 0.0 ± 0.0  
Post Mixed Culture 1 138.8 ± 1.4 0.1 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
Δ Concentration -1.1 ± 1.8 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
 
Table 32 – Pre- and Post-Incubation Analysis: Effects of Mixed Culture on Diazepam 2 
 Concentration (ng/mL) 
Sample DZ NDZ OX TZ 
Pre Mixed Culture 2 159.3 ± 1.1 0.1 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
Post Mixed Culture 2 154.5 ± 1.5 0.1 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
Δ Concentration -4.8 ± 0.7 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
 
Samples were incubated with 100 µL each of E. coli and B. fragilis, and C. 
perfringens.  As seen with the C. perfringens samples, there was minimal change in DZ 
concentration.  This supported the supposition that the presence of C. perfringens 
stabilized the analyte and prevented unassisted degradation as well as the proposed 
conversions by E. coli and B. fragilis.  As expected, there were negligible changes in 
concentration detected for NDZ, OX, and TZ.   
 
4.6.7 Flunitrazepam Blanks 
 
Analysis of the FLU drug blanks exhibited a decrease in concentration of the 
target analyte similar to that seen with DZ.  FLU Drug Blank 1 (Table 33) produced an 
average change in concentration of -25.9 ± 6.3 ng/mL and FLU Drug Blank 2 (Table 34) 
an average difference of -40.2 ± 0.8 ng/mL.  Unlike what was observed in the DZ blank 
experiments, however, there was a corresponding increase in concentration for FLU 




concentration of 15.7 ± 0.1 ng/mL (FLU Drug Blank 1) and 15.1 ± 0.2 ng/mL (FLU Drug 
Blank 2). 
 
Table 33 – Pre- and Post-Incubation Analysis: Flunitrazepam Drug Blank 1 
 Concentration (ng/mL) 
Sample FLU 7AM NDES 
Pre FLU Blank 1 182.7 ± 5.3 0.1 ± 0.0 0.0 ± 0.0 
Post FLU Blank 1 156.8 ± 2.1 15.9 ± 0.1 0.0 ± 0.0 
Δ Concentration Average -25.9 ± 6.3 +15.7 ± 0.1 0.0 ± 0.0 
 
Table 34 – Pre- and Post-Incubation Analysis: Flunitrazepam Drug Blank 2 
 Concentration (ng/mL) 
Sample FLU 7AM NDES 
Pre FLU Blank 2 186.6 ± 3.7 0.2 ± 0.0 0.0 ± 0.0 
Post FLU Blank 2 146.4 ± 2.9 15.3 ± 0.2 0.0 ± 0.0 
Δ Concentration Average -40.2 ± 0.8 +15.1 ± 0.2 0.0 ± 0.0 
 
FLU Drug Blank samples maintained sterility throughout the duration of the 
experiments.  Mass balance of the reaction indicated that approximately half of the 
decrease in FLU concentration between pre- and post-incubation samples was 
contributed to conversion to metabolite 7AM.  This was most likely in response to the 
incubation conditions and duration which led to an unassisted degradation.  These 
responses were supported by the processed sample stability study performed in the DZ 
and FLU method validation (Section 3.3.8).  In the stability study conducted for the 500 
ng/mL sample, FLU demonstrated an average -54.1 ng/mL in concentration while 7AM 
produced an average of +11.5 ng/mL from T=0 to T=48 hours.  A visual representation 









































The remaining mass balance discrepancy, -8.3 ng/mL in sample 1 and -23.3 
ng/mL in sample 2, between pre- and post-incubation FLU in the analyte blank 
concentrations was otherwise unaccounted for.  Mass balance for the reaction was 
calculated by converting the original FLU concentration to moles and subtracting the 
number of moles of 7AM produced.  The remainder was reconverted back to grams of 
FLU.  This was the most accurate way to account for differences in mass between loss 
of FLU and production of 7AM.  NDES was absent in both pre- and post incubation 
blanks.  This suggested that FLU likely performed a partial, unassisted degradation to a 




4.6.8 Effects of E.coli on FLU 
 
Analysis of the effects of E. coli on FLU concentration resulted in an average 
concentration difference of –112.4 ± 2.6 ng/mL in sample 1 and -142.0 ± 3.3 ng/mL in 
sample 2.  These results were summarized in Tables 35 and Table 36, respectively.  
 
Table 35 – Pre- and Post-Incubation Analysis: Effects of E. coli on Flunitrazepam 1 
 Concentration (ng/mL) 
Sample FLU 7AM NDES 
Pre E.coli 1 142.0 ± 1.8 0.1 ± 0.0 0.0 ± 0.0 
Post E.coli 1 29.6 ± 0.9 93.5 ± 1.3 0.0 ± 0.0 
Δ Concentration Average -112.4 ± 2.6 +93.4 ± 1.3 0.0 ± 0.0 
 
Table 36 – Pre- and Post-Incubation Analysis: Effects of E. coli on Flunitrazepam 2 
 Concentration (ng/mL) 
Sample FLU 7AM NDES 
Pre E.coli Blank 2 175.5 ± 3.6 0.2 ± 0.0 0.0 ± 0.0 
Post E.coli Blank 2 33.4 ± 0.3 15.3 ± 0.6 0.0 ± 0.0 
Δ Concentration Average -142.0± 3.3 +93.7 ± 0.6 0.0 ± 0.0 
 
  
As seen in the FLU drug blank samples, 7AM registered an increase in post-
incubation samples.  However, the conversion of FLU to 7AM occurred to a greater 
extent in samples inoculated with E. coli.  Of the 112.4 ng/mL of FLU converted, an 
average of 93.4 ng/mL was recovered in the form of 7AM in sample 1.  Mass balance of 
the reaction indicated that approximately 9.0 ng/mL of the original FLU concentration 
was unaccounted for in sample 1 and 38.4 ng/mL in sample 2.  Of the 142.0 ng/mL of 
FLU converted in sample 2, only 93.7 ng/mL was converted to 7AM.  The results can be 






Figure 22 – Effects of E. coli on Pre and Post-Incubation Concentrations of 





























In the FLU drug blanks, 15.1-15.7 ng/mL of 7AM was recovered from the post-
incubation samples.  This was similar to the conversion seen in sample 2.  Both 
samples demonstrated similar OD values and turbidity.  This supported the theory that 
FLU was being converted to an additional metabolite not monitored in this analysis.  
There were several possible explanations for the discrepancies between FLU 
disappearance and the appearance of 7AM.  Based on the extent of FLU conversion, it 
was evident that 7AM was the major metabolite produced by the biotransformation 




the reaction indicated that these bacterial species produced an alternative metabolite or 
metabolites as well.   
There were several possible explanations for the discrepancies between FLU 
disappearance and the appearance of 7AM.  3-hydroxyflunitrazepam was a potential 
candidate that should be included in future analysis and is depicted in Figure 23.  
 



















Additionally, Malanciuc et al. published a metabolism of FLU scheme that 
included several additional compounds.58  These compounds were not included in this 
research because 7-acetamino-flunitrazepam and 7-amino-nor-flunitrazepam are not 
directly FLU metabolites.  They are produced by the conversion of 7AM and can be 
seen in Figure 24.  Either of these were potential minor metabolites that would have 
explained the slight concentration differences between the disappearance of FLU and 





































7-acetamino-flunitrazepam  7-amino-nor-flunitrazepam 
 
As suggested with DZ, additional FLU and 7AM metabolites may account for the 
discrepancies in mass balance of the reaction.  Kinetic studies on the rate of 
disappearance of FLU and rate of appearance of 7AM might also provide valuable 
information that could aid in unidentified minor metabolite identification.  Additionally, 
analysis of the post-incubation sample via LC-MS/MS in full scan mode might offer 
some information concerning the m/z of the unidentified compound. 
 
 




4.6.9 Effects of B. fragilis on FLU 
  
Analysis of the effects of B. fragilis on FLU concentration produced turbid 
samples and  demonstrated an average concentration difference of -151.5 ± 2.7 ng/mL 
in sample 1 and -117.9 ± 3.2 ng/mL in sample 2.  In both instances, this represented 
complete degradation of FLU.  These results were summarized in Table 37 and Table 
38, respectively. 
 
Table 37 – Pre- and Post-Incubation Analysis: Effects of B. fragilis on Flunitrazepam 1 
 Concentration (ng/mL) 
Sample FLU 7AM NDES 
Pre B. fragilis 1 151.5 ± 2.7 9.7 ± 0.1 0.0 ± 0.0 
Post B. fragilis 1 0.0 ± 0.0 129.3 ± 0.6 0.0 ± 0.0 
Δ Concentration Average -151.5 ± 2.7 +119.6 ± 0.7 0.0 ± 0.0 
 
 
Table 38 – Pre- and Post-Incubation Analysis: Effects of B. fragilis on Flunitrazepam 2 
 Concentration (ng/mL) 
Sample FLU 7AM NDES 
Pre B. fragilis 2 117.9 ± 3.2 8.6 ± 0.1 0.0 ± 0.0 
Post B. fragilis 2 0.0 ± 0.0 103.3 ± 0.9 0.0 ± 0.0 
Δ Concentration Average -117.9 ± 3.2 +94.8 ± 0.9 0.0 ± 0.0 
 
 
In sample 1, the 7AM concentration increased by +119.6 ng/mL. Mass balance of 
the reaction suggested that approximately 8.6 ng/mL of the original FLU was converted 
to a compound other than those that were monitored in this method.  Approximately 3.7 







Figure 25 – Effects of B. fragilis on Pre and Post-Incubation Concentrations of 


































4.6.10 Effects of C. perfringens on FLU 
  
The effects of C. perfringens on FLU were similar to those produced by B. 
fragilis.  Incubation with C. perfringens resulted in complete reduction of FLU between 
pre- and post-incubation samples for a total of -164.5 ± 4.7 ng/mL in sample 1 and -






Table 39 – Pre- and Post-Incubation Analysis: Effects of C. perfringens on 
Flunitrazepam 1 
 Concentration (ng/mL) 
Sample FLU 7AM NDES 
Pre C. perfringens 1 164.5 ± 4.7 0.1 ± 0.0 0.0 ± 0.0 
Post C. perfringens 1 0.0 ± 0.0 134.0 ± 0.9 0.0 ± 0.0 
Δ Concentration Average -164.5 ± 4.7 +133.8 ± 0.9 0.0 ± 0.0 
 
 
Table 40 – Pre- and Post-Incubation Analysis: Effects of C. perfringens on 
Flunitrazepam 2 
 Concentration (ng/mL) 
Sample FLU 7AM NDES 
Pre C. perfringens 2 137.2 ± 2.1 0.1 ± 0.0 0.0 ± 0.0 
Post C. perfringens 2 0.0 ± 0.0 124.0 ± 0.7 0.0 ± 0.0 
Δ Concentration Average -137.2 ± 2.1 +123.9 ± 0.7 0.0 0.0 
 
 
In sample 1, the 7AM concentration increased by +133.8 ng/mL.  Mass balance 
of the reaction suggested that approximately 16.4 ng/mL of FLU was converted to an 
alternative compound or metabolite.  In sample 2, only 0.1 ng/mL of the original FLU 
concentration was unrecovered.  These effects were depicted in Figure 26.  The 
potential minor metabolites proposed for E. coli and B. fragilis biotransformations were 
also candidates with C. perfringens inoculates, however, further investigations would be 






Figure 26 – Effects of C. perfringens on Pre and Post-Incubation Concentrations of 




































4.6.11 Effects of a Mixed Culture on FLU 
  
The effects of the mixed culture reduced the initial FLU concentrations by -103.3 
± 2.6 ng/mL in sample 1 and -149.6 ± 2.0 ng/mL in sample 2, both of which represented 






Table 41 – Pre- and Post-Incubation Analysis: Effects of Mixed Culture on 
Flunitrazepam 1 
 
 Concentration (ng/mL) 
Sample FLU 7AM NDES 
Pre Mixed Culture 1 103.3 ± 2.6 3.5 ± 0.1 0.0 ± 0.0 
Post Mixed Culture 1 0.0 ± 0.0 86.9 ± 1.2 0.0 ± 0.0 
Δ Concentration Average -103.3 ± 2.6 +83.4 ± 1.2 0.0 ± 0.0 
 
 
Table 42 – Pre- and Post-Incubation Analysis: Effects of C. perfringens on 
Flunitrazepam 2 
 Concentration (ng/mL) 
Sample FLU 7AM NDES 
Pre Mixed Culture 2 150.9 ± 2.9 3.9 ± 0.0 0.0 ± 0.0 
Post Mixed Culture 2 0.0 ± 0.0 123.7 ± 0.0 0.0 ± 0.0 
Δ Concentration Average -149.6± 2.0 +119.9± 0.0 0.0 ± 0.0 
 
FLU demonstrated concentration loss for each bacterial species individually as 
well as the mixture of bacteria.  Mixed culture samples produced the complete 
transformation of FLU as seen with B. fragilis and C. perfringens.  Mass balance of the 
reaction demonstrated that approximately 7.2 ng/mL of FLU in sample 1 and 14.1 
ng/mL in sample 2 was not recovered in the form of 7AM.  Data are depicted in Figure 
27.  As with the other cultures, data suggested that an alternative metabolite or multiple 
metabolites were likely being produced. However, the identity of these structures will 





Figure 27 – Effects of Mixed Culture on Pre and Post-Incubation Concentrations of 



































 The data exhibited by the effects of E. coli, B. fragilis, C. perfringens, and mixed 
culture was consistent with that published by Robert and Drummer, detailed in section 
1.1.3.16  In this study, Robertson and Drummer studied effects of 8 GI bacteria on 
clonazepam, flunitrazepam, and nitrazepam in blood.  They found that all three 
compounds were converted to their respective 7-amino metabolites, though the rate of 
conversion varied amongst the different species.  However, analysis was limited by their 
methodology.  The experimental run time was 25 minutes whereas the previously 
validated LC-MS/MS method was 8 minutes.  LOQ values for their analytes were all 10 




FLU at 0.5 and 7AM at 0.1 ng/mL.  In addition, they did not prepare analyte blanks for 
analysis.  As seen in this research, DZ and FLU both underwent a partial, unassisted 
degradation when incubation under experimental conditions and duration.  These 
authors also performed temperature studies to study the effect of temperature on 






 An LC-MS/MS method was previously validated for the simultaneous detection, 
identification, and quantitation of the benzodiazepines DZ, FLU, and their respective 
metabolites which were recovered from RCM using SPE (Chapter 3).  The method was 
applied to experimental explorations involving bacterial biotransformation of the drugs of 
abuse DZ and FLU.   
Pre- and post-incubation aliquots were extracted and analyzed via LC-MS/MS.  
Analytes and metabolites were evaluated for acceptable peak shape, retention time, ion 
ratios, and S/N ≥ 3 for detection as well as bias and precision within ±20% for 
quantitation.  A series of blanks was prepared in RCM and incubated alongside samples 
inoculated with bacteria.  
Analysis and mass balance of the DZ blank suggested the analyte must undergo 
a partial, unassisted degradation when incubated at 37°C for 48 hours.  However, NDZ, 
OX, nor TZ registered an increase from pre- to post-incubation concentrations.  The DZ 
degradation product was therefore unidentified.  Analysis of the FLU drug blanks 




increase in concentration in 7AM metabolites in the post-incubation samples that 
accounted for some of the FLU loss. 
Analysis of the effects of E. coli and B. fragilis on DZ concentration demonstrated 
an average concentration difference greater than that seen in the blanks.  In 
accordance with drug blank samples, neither NDZ, OX, nor TZ registered a detectible or 
quantifiable increase from pre- to post-incubation concentrations.  The discrepancies 
between blank and biotransformation study samples indicated that there may be 
additional factors contributing to the transformation of DZ when incubated with E.coli or 
B. fragilis.  A possible explanation was that DZ was being converted to a compound 
other than the human metabolites NDZ, OX, and TZ monitored.  In this case, E. coli and 
B. fragilis possessed a specific enzyme or combination of enzymes that were capable of 
cleaving DZ to form some type of alternative metabolite. Additional experimental and 
literature review may offer some guidance.   
There were negligible changes in concentration detected for NDZ, OX, and TZ in 
samples inoculated with C. perfringens.  However, there was minimal change in DZ 
concentration as well.  These findings supported the theory of E. coli and B. fragilis 
were responsible for the concentration discrepancies between the DZ drug blanks and 
their respective biotransformation studies.  The small change in DZ concentration, 
however, was unique.  The difference was small enough that it could potentially be 
explained by differences in instrumental response.  However, the C. perfringens 
samples were incubated alongside the other blanks and inoculates, and loss of DZ 
concentration similar to that seen in the drug blank samples was expected.  Since DZ 




stabilized the analyte and prevented degradation. The effects of mixed culture resulted 
in similar responses to those seen in C. perfringens.  This supported the supposition 
that the presence of C. perfringens stabilized the analyte and prevented the proposed 
degradation by E. coli and B. fragilis. 
E. coli, B. fragilis, C. perfringens, and a mixture of the three species were all 
capable of transforming FLU to 7AM to varying extents in RCM.  E. coli converted the 
majority of FLU but was not as efficient as the anaerobic species.  7AM exhibited an 
increase in concentration between pre- and post-incubation samples which accounted 
for some of the FLU loss. However, not all of the original FLU concentration was 
recovered as 7AM as evidenced by mass balance of the reaction.  This could have 
been attributed to transformation of FLU into an additional metabolite that was not 
monitored such as 3-hydroxyflunitrazepam.  Another possibility was conversion of 7AM 
to 7-acetamino-flunitrazepam and/or 7-amino-nor-flunitrazepam.  However, further 
analysis would be required to determine the presence and identity of these or other 







Chapter 5 – A Validated Method for the Quantitation of 
Cocaine, Fentanyl, and Metabolites in Reinforced Clostridial 






In Chapter 3, a method was developed and validated for the quantitation of DZ 
and FLU in RCM.  This chapter focused on expanding the previous methodology to 
investigate other analytes of interest. 
A novel LC-MS/MS method was developed and validated for simultaneous 
analysis and quantitation of cocaine (COC) and metabolites anhydroecgonine methyl 
ester (AEME), benzoylecgonine (BZE), cocaethylene (CE), ecgonine methyl ester 
(EME), m-hydroxycocaine (mHC), and norcocaine (NC) as well as fentanyl (FENT), and 
metabolites norfentanyl (NF), and despropionyl fentanyl (DESP) in RCM.  RCM is a 
bacterial nutrient medium, the components of which were discussed in Table 2. 
COC and FENT are classified by the DEA as Schedule II drugs of abuse.24  They 
were selected as the target analytes due to the importance in analytical and forensic 
toxicology.  Human metabolic studies have been well documented and the analyte and 
metabolite standards were commercially available.   
According to the Substance Abuse and Mental Health Services Administration 
(SAMHSA) - National Survey on Drug Use and Health there were approximately 1.1 
million COC users in the United States in 2012.64  COC is most commonly snorted, 
smoked, or injected, and acts as a CNS stimulant.  It is considered to be highly 
addictive compound and is linked to adverse health effects including increase in blood 




COC has been known to cause cardiovascular complications, seizures, and stroke in 
users as well.  Human metabolism of COC has been extensively studied, and many 
metabolites have been identified.  Only the first generation metabolites of AEME, BZE, 
CE, EME, mHC, and NC were investigated for the purposes of this research. The 
metabolism scheme for COC is displayed in Figure 28.50,51,65-82 65-
68,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81 
Figure 28 – Human Metabolites of Cocaine 
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FENT is a synthetic opiod analgesic.  It is classified as both a drug for medicinal 
purposes and a drug of abuse.  For medical purposes, it is known as Actiq®, 
Duragesic®, and Sublimaze®.24, 64, 82  It is most often used in various forms of pain 
management.  This drug is commonly administered as an injection, but can also be 
seen in transdermal patches as well as lozenges.  It binds to opiate receptors in the 
body and causes nausea, sedation, respiratory depression, respiratory arrest, and 
coma.24, 64, 82  Human metabolites include NFENT and DESP. The metabolism scheme 
for FENT is displayed in Figure 29.51,84-8851 
, 83,84,85,86,87  
Figure 29 – Human Metabolites of Fentanyl 






























Analyte reference standards for COC, AEME, BZE, CE, EME, NC, FENT, and 
NFENT as 1.0 mg/mL, and cocaine-d3 (COC-d3), benzoylecgonine-d3 (BZE-d3), 
cocaethylene-d3 (CE-d3), ecgonine methyl ester-d3 (EME-d3), norcocaine-d3 (NC-d3), 
fentanyl-d5 (FENT-d5), and norfentanyl-d5 (NFENT-d5) as 100 µg/mL were purchased 
from Cerilliant® (Round Rock, TX).  The m-hydroxycocaine (mHC) was purchased as a 
1.0 mg solid from Sigma-Aldrich ® (St. Louis, MO) and despropionyl-3-methylfentanyl 
(despropionyl fentanyl) (DESP) was purchased as a 1.0 mg solid from Enzo ® Life 
Sciences (Farmingdale, NY).  Both of these standards were dissolved in 1 mL of MeOH 
for working standard and dilution preparations.   
Ammonium acetate, ammonium hydroxide (NH4OH), FA eluent additive for LC-
MS, hydrochloric acid (HCl), and LC-MS CHROMASOLV® ACN and MeOH were 
purchased from Sigma-Aldrich®.  The IPA (Optima™ LC/MS) was purchased from 
Fischer Scientific and HPLC grade EA from JT Baker® (Center Valley, PA).  Strata™-X-
Drug B Strong Cation Mixed Mode 60mg/3mL cartridges were obtained from 
Phenomenex® (Torrance, CA).  The narrow bore ZORBAX Eclipse XDB-C8 (2.1 mm x 
150 mm x 5 µm) column affixed with a ZORBAX Eclipse XDB-C8 (2.1 mm x 12.5 mm x 
5 µm) guard cartridge were obtained from Agilent Technologies (Santa Clara, CA).  










5.2.2 Sample Preparation 
 
An initial calibration curve was prepared from working solutions in buffer and 
plotted at 0.05, 0.1, 0.25, 0.5, 1, 5, 10, 25, 50, 100, and 200 ng/mL.  Calibration curves 
for each analyte in buffer can be seen in Appendix D.  Three different SPE methods 
were evaluated for recovery of COC, FENT, and metabolites.  Reagents and solvents 
consisted of acetonitrile (ACN), ethyl acetate (EA), isopropyl alcohol (IPA), formic acid 
(FA), methanol (MeOH), and ammonium hydroxide (NH4OH).  Details of the methods 
are shown in Figure 30 and Figure 31. 
 




Cartridge: Strata-X-Drug B 
      
 
SPE 2 
Cartridge: Strata-X-Drug B 
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Cartridge: Strata-X-Drug b 
     
 
Three working solutions containing all ten analytes at 10,000 ng/mL (WS1), 1000 
ng/mL (WS2), and 10 ng/mL (WS3) in water/acetonitrile:methanol (80/20 v/v) were used 
to prepare the dilution sets required in the method validation studies.  An internal 
standard working solution consisting of the seven deuterated standard compounds was 
prepared at 2500 ng/mL.  The RCM matrix was composed of ten 100 mL aliquots of 
RCM (3.8 g RCM in 100 mL of DI water) which were prepared, pooled, and then 
autoclaved at 121°C for 15 minutes.   
All samples were spiked with 200 µL of 0.1N HCl to ensure pH between 4.0 and 
6.0 which was necessary for extraction.  SPE was used to isolate target analytes from 
media components.  Extractions were performed at 3 concentrations spanning the 












The Strata™-X-Drug B cartridges are based on a polymeric strong-cation mixed 
mode sorbent specifically designed for basic drugs of abuse.  These cartridges and 
SPE 1 method were chosen because they demonstrated the greatest responses for the 
analytes of interest and metabolites across the three concentrations.  The cartridges did 
not require conditioning steps which was advantageous because SPE required less 
time and solvent per sample.  This also reduced the amount of hazardous waste 
produced as well.  
Samples (1 mL) were directly loaded onto the Strata™-X-Drug B cartridges (no 
conditioning) and washed with 1 mL of 0.1N HCl.  Wash 1 was designed to minimize 
salt content and other polar compounds that could interfere with instrumental analysis.  
Cartridges were also washed with 1 mL of MeOH (Wash 2) to minimize the nonpolar 
matrix constituents, and then dried under full vacuum for 10 minutes.  Samples were 
eluted with 1 mL of a freshly prepared mixture of EA:IPA:NH4OH (70:20:10 v/v/v), dried 
under nitrogen, and reconstituted in water/acetonitrile:methanol (80/20 v/v). 
. 
5.2.3 Instrumental Analysis 
 
Method development and analysis were performed using LC-MS/MS.  
Instrumentation was the same used to develop and validate the DZ and FLU method in 
Chapter 3.  Samples (2 µL) were injected at a flow rate of 0.250 mL/min.  The buffer 
system consisted of 20 mM ammonium acetate adjusted to pH 2.7 with FA (A) and 
acetonitrile/methanol (50/50 v/v) (B).  Analytes were separated using a gradient elution 
program of 20% B for 2 minutes, to 45% B over 10.5 minutes, back to original 




time was 14 minutes followed by a 2 minute post-run at 20% B to ensure stable column 
conditions before the next injection. 
The AJS ESI source was operated in the positive mode and parameters were 
optimized using Source and iFunnel Optimizer with a 100 ng/mL sample containing all 
of the target analytes, metabolites, and standards.  The gas temperature was optimized 
at (265°C), gas flow (19 L/min), nebulizer (50 psi), sheath gas temperature (350°C), 
sheath gas flow (11 L/min), capillary (3250 V), ΔEMV (200), fragmentor (380 V), and 
cell acceleration (2 V).  The column was maintained at 37°C and the autosampler at 
4°C.   
MassHunter™ Optimizer software was used to determine the best MRM 
transitions for each analyte of interest as well as their corresponding deuterated 
standards.  The software provided up to four ion transitions for each analyte,  the results 
for which can be seen in Appendix E.  All of the suggested ions were included in the 
initial calibration.  The two ion transitions that demonstrated the greatest signal 
response while also maintaining stable ion ratios across the calibration range were 
selected as the quantifier and qualifier ions for each analyte. 
MRM data were only acquired in a narrow window based upon the RT of the 
analyte of interest.  Because some of the ions had similar ion transitions, the narrow 
range of acquisition increased the selectivity for each individual analytes.  Samples 
were quantified by comparing the peak area response ratio of the target analyte to that 
of the corresponding deuterated standard.  RT, quantifier and (qualifier) ion transitions, 
CE, ion ratios, and deuterated standard selection for each analyte is summarized in 



























COC 9.0 304.2 182.0 13 8.7 COC-d3 
   (150.0) 20   
COC-d3 9.0 307.2 185.0 15   
       
AEME 2.05 182.1 118.0 25 72.0 EME-d3 
   (122.1) 17   
       
BZE 6.0 290.1 168.0 13 35.8 BZE-d3 
   (104.9) 20   
BZE-d3 6.0 293.1 171.0 13   
       
CE 11.2 318.2 196 13 9.4 CE-d3 
   (150.0) 20   
CE-d3 11.2 321.2 199.0 13   
       
EME 1.6 200.1 82.1 29 10.5 EME-d3 
   (150.0) 20   
EME-d3 1.6 203.1 (185.0) 13   
       
mHC 5.65 320.2 182.0 13 19.9 BZE-d3 
   (82.0) 20   
       
NC 9.7 290.1 168.0 9 64.8 NC-d3 
   (136.0) 17   
NC-d3 9.7 293.1 171.0 9   
       
FENT 13.2 337.2 (105.0) 45 84.5 FENT-d5 
   (188.1) 21   
FENT-d5 13.2 342.3 188.0 19   
       
NFENT 7.0 233.2 84.0 15 4.2 NFENT 
   (93.9) 31   
NFENT-
d5 
7.0 238.0 84.0 15   
       
DESP 12.5 281.2 105.0 31 73 FENT-d5 





The separation and MRM transitions of the analytes can be seen in the 
chromatogram in Figure 32.  The purpose of chromatographic separation in this method 
was to minimize the co-elution of target analytes and their respective metabolites.  
These compounds were similar in structure and many utilized the same ion transitions, 
which can lead to ionization effects that affect quantitation.  Maximizing analyte 
separation and limiting MRM data acquisition to the narrow window incorporating 
analyte retention time enhanced the selectivity for each individual analytes.   
 
Figure 32 – MRM of Cocaine, Fentanyl, and Respective Metabolites in RCM 
 
 
Unlike the DZ and FLU method developed in Chapter 3, deuterated standards 
were not available for all of the metabolites of interest.  Internal standards for these 
compounds were selected based upon compounds with similar structure as well as RT, 
a feature of analyte response to the column, buffer system, and elution gradient. 
 
5.2.4 Method Validation 
 
 Method validation definitions and parameters were detailed in Chapter 1.  The 
presented method was fully validated and included a calibration model, interference 
studies, carryover effects, ionization suppression and enhancement, ME, RE, PE, bias 













5.3.0 Results and Discussion 
 
 
5.3.1 Calibration Model 
 
 Calibration and QC standards were prepared in media using WS1, WS2, and 
WS3, and the internal standard working solution.  Final calibrations were based on a 10-
point model of 0.1, 0.25, 0.5, 1, 5, 10, 25, 50, 100, and 200 ng/mL for the analytes and 
25 ng/mL for the corresponding deuterated standards.  Calibrations were determined 
using a linear model excluding the origin and with 1/x weighting.  Correlation coefficients 
were >0.99 (n=5) for all analytes of interest in RCM, and can be seen in Appendix F.  
Calibration range, slope, y-intercept, R2, LOD, and LOQ values are summarized in 
Table 44. 
 
Table 44 – Calibration Curve Data, LOD, and LOQ for Cocaine, Fentanyl, and 














COC 0.1 - 200 4.11 -5.71 0.999 0.1 0.1 
AEME 10 - 200 1.31 5.29 0.995 10 10 
BZE 0.1 - 200 4.49 -0.356 0.997 0.1 0.1 
CE 0.25 - 200 4.53 -2.71 0.996 0.25 0.25 
EME 5 - 200 1.73 11.8 0.992 5.0 5.0 
mHC 0.25 - 200 1.09 -4.90 0.995 0.1 0.25 
NC 0.25 - 200 3.87 1.09 0.996 0.1 0.25 
FENT 0.25 - 200 5.70 3.43 0.995 0.1 0.25 
NFENT 0.5 - 200 8.34 -19.2 0.997 0.5 0.5 
DESP 0.25 - 200 5.85 -1.24 0.993 0.1 0.25 
 
 
5.3.2 Interference Studies 
 
Ten RCM samples were prepared, pooled, and then autoclaved for interference 
and other validation studies.  Blank matrix samples were extracted and then analyzed 




upon retention time, peak shape, and ion ratio.  Some of the analyte responses were 
indicative of matrix effects, however all of the responses failed to satisfy analyte 
identification criteria of RT, peak shape, and ion ratios.  Extent of matrix effects were 
examined in greater detail using the Matuszewski methods in Section 5.3.4.28 
Deuterated standard blanks at 25 ng/mL were also examined for possible 
interferences that could be caused by impurities or similar fragmentation patterns of 
analyte and internal standards.  Interferences were negligible based upon the previously 
established identification criteria.  
 
5.3.3 Carryover Analysis 
 
 To determine carryover effects, samples were prepared at the two highest 
calibration points, 100 and 200 ng/mL, as well as two higher concentrations of 300 and 
400 ng/mL.  Each sample injection was followed by an extracted blank sample injection.  
Analyte carryover was detected at all four concentrations.  To minimize or eliminate 
these effects, blank samples were injected between each sample analysis. 
 
5.3.4 Ionization Suppression/Enhancement and Recovery 
 
 ME, RE, and PE were all calculated using the Matuszewski equations and 
methods which are defined in Section 1.5.3.  Three sets of samples were prepared at 
three concentrations to span the range of LOD and LOQ values of the analytes of 






Table 45 – Matrix Effects, Recovery, and Process Efficiency for Cocaine and 
Metabolites in RCM 
 
Analyte COC AEME BZE CE EME mHC NC 
 
 
High (200 ng/mL) 
ME (%) 103.0 49.4 107.1 87.9 87.5 104.7 96.7 
RE (%) 97.7 136.1 97.6 97.9 98.9 105.7 98.2 
PE (%) 100.6 67.2 104.5 86.0 86.5 110.6 94.9 
        
 Medium/High (25 ng/mL) 
ME (%) 95.6 70.2 98.1 97.1 100.8 142.7 98.3 
RE (%) 94.0 225.4 94.4 94.3 99.6 94.3 94.0 
PE (%) 89.9 158.2 92.7 91.6 100.4 134.7 92.4 
  
 Medium/Low (5 ng/mL) 
ME (%) 94.9 14.7 106.2 100.8 91.7 256.8 102.4 
RE (%) 99.5 73.8 101.8 98.9 105.4 109.2 100.2 
PE (%) 94.4 10.9 108.1 99.7 96.7 290.4 102.6 
  
 Low (0.5 ng/mL) 
ME (%) 79.5 - 88.0 81.0 - 144.7 85.3 
RE (%) 92.8 - 95.0 94.8 - 100.3 92.8 






Table 46 – Matrix Effects, Recovery, and Process Efficiency for Fentanyl and 









    
 High (200 ng/mL) 
ME (%) 88.0 93.9 93.6 
RE (%) 98.8 99.7 98.7 
PE (%) 86.9 93.7 92.4 
    
 Medium/High (25 ng/mL) 
ME (%) 96.9 97.7 97.7 
RE (%) 94.9 94.5 96.0 
PE (%) 92.0 92.3 93.8 
    
 Medium/Low (5 ng/mL) 
ME (%) 102.9 103.1 106.0 
RE (%) 99.9 100.6 98.3 
PE (%) 102.8 103.7 104.3 
  
 Low (0.5 ng/mL) 
ME (%) 88.4 81.0 85.8 
RE (%) 95.6 95.0 94.8 
PE (%) 84.5 76.9 81.3 
 
The ME, RE, and PE reflect the ability and efficiency of the SPE method.  Matrix 
effects showed slight ionization enhancement for COC, BZE, and mHC at high 
concentration.  The other analytes experienced ionization suppression with ME ranging 
from 87.5% to 96.7%.  RCM is a complex medium and both ionization enhancement as 
well as suppression effects can be contributed to matrix components.    
AEME experienced matrix effects of 49.4% even at high concentration.  This 
apparent suppression was a result of several factors.  There was no deuterated AEME 
standard in this method, and using EME-d3 may not have been adequate for accurate 
quantitation.  Additionally, AEME was a very polar molecule and eluted near the solvent 




AEME eluted soon after EME and their MRM transition peaks exhibited some tailing.  
These two molecules differed only by a water molecule and the most abundant 
transition of EME was the 182.0 m/z of AEME.  This transition was not selected to be 
monitored for EME, but with the analytes eluting so close together, the RT window could 
not be narrowed enough to isolated the analyses. All of these factors could explain the 
method effects on AEME individually, but most likely a combination of effects was 
responsible.  The RE and PE of AEME were also affected across all concentration 
levels.  Analysis of AEME will be very limited in this method.  
ME were more prominent for the other analytes at low concentration with 
suppression ranging from 79.5 to 85.8%.  mHC is the only analyte at low concentrations 
to express ionization enhancement at 144.7%.  This could be attributed to the lack of 
deuterated mHC.  BZE may not have accurately defined the responses of mHC at lower 
concentrations which resulted in increased ionization enhancement.  It could also be 
attributed to matrix components that interfered with mHC ionization and signal 
response. 
Recovery ranged from 92.8 to 109.2% across all concentration levels for both 
sets of analytes and metabolites (except AEME).  This indicated that the SPE method 
was efficient in retrieving analytes from the matrix.  However, the method was not as 
successful in removing matrix components as evidenced by the extent of ME on all 
analytes.  Perhaps an additional wash step or maybe a syringe filtering could be applied 
to improve the clean up.  The RE % was not calculated for EME at 0.5 ng/mL because it 




PE was designed to take ionization effects as well as recovery into account. PE 
ranged from 86.0 to 110.6% for high and medium concentration levels for COC, BE, CE, 
NC, FENT, NFENT, and DESP, and  73.8 to 84.5% at low concentration.  PE ranged 
from 110.6 to 290.4% for mHC while recoveries only ranged from 94.3-109.2% across 
all concentrations.  The high PE values are therefore due to matrix effects.  Over all, the 
FENT and metabolites were much less affected by ME than COC and metabolites.  
FENT analytes also had significantly better recoveries across all concentration levels. 
 
5.3.5 Bias and Precision 
 
Bias and precision (within-run precision) and repeatability (between-run 
precision) were defined in Chapter 1.  The values were calculated using Equation 4, 
Equation 5, and Equation 6, respectively.  Analysis of percent bias and within-run and 
between-run precision was conducted at four different concentrations 100 (high), 10 
(medium/high), 5 (medium/low), and 0.5 ng/mL (low) for COC, BZE, CE, mHC, NC, 
FENT, NFENT, and DESP.  EME studies were conducted only at the high, 
medium/high, and medium/low concentrations, and AEME only at the high and 
medium/high concentrations due to LOD and LOQ limitations.  Data is summarized in 






Table 47 – Bias, Within-Run and Between-Run %CV for Cocaine and Metabolites in 
RCM 
 
Analyte COC AEME BZE CE EME mHC 
 
NC 
        
 High (100 ng/mL) 
Bias (%) -7.7 -9.6 -7.4 -8.3 -11.0 -13.2 -9.9 
Within-Run (%) 2.2 7.1 2.1 1.7 1.2 3.2 2.5 
Between-Run (%) 6.8 7.3 4.5 3.5 3.8 4.3 5.8 
        
 Medium/High (10 ng/mL) 
Bias (%) -8.2 3.1 -8.6 -5.7 -5.8 -11.4 10.3 
Within-Run (%) 2.0 3.4 2.7 1.8 1.6 2.2 1.6 
Between-Run (%) 10.1 12.2 10.9 9.8 12.8 11.3 9.9 
        
 Medium/Low (5 ng/mL) 
Bias (%) -5.2 - -3.6 -12.7 -16.0 -19.6 -9.0 
Within-Run (%) 1.7 - 3.0 1.8 1.0 2.2 6.0 
Between-Run (%) 7.9 - 4.5 8.1 4.1 3.9 11.0 
        
 Low (0.5 ng/mL) 
Bias (%) -17.4 - -5.0 -18.4 - -15.8 -11.1 
Within-Run (%) 4.4 - 7.2 7.8 - 7.2 7.0 














    
 High (100 ng/mL) 
Bias (%) -11.6 -6.5 -11.5 
Within-Run (%) 1.1 1.4 2.1 
Between-Run (%) 3.3 4.3 3.6 
    
 Medium/High (10 ng/mL) 
Bias (%) -10.4 -7.1 -9.7 
Within-Run (%) 2.2 1.5 1.1 
Between-Run (%) 11.9 9.5 13.8 
    
 Medium/Low (5 ng/mL) 
Bias (%) -19.0 -5.8 -15.2 
Within-Run (%) 2.5 1.9 1.1 
Between-Run (%) 8.1 8.2 7.2 
    
 Low (0.5 ng/mL) 
Bias (%) -11.3 -18.8 -15.0 
Within-Run (%) 6.1 5.3 5.8 
Between-Run (%) 7.0 7.2 6.7 
 
 
Within-run precision ranged from 1.1 to 7.8% across each of the concentration 
levels while  between-run precision ranged from 3.3 to 13.8%.  For most analytes the 
higher concentration sample sets demonstrated the narrowest range of values.  
Generally, bias and precision values increased as concentration values decreased 
toward the LOD and LOQ values of the analytes.  Even though the acceptable range is 
±20% is the same for all concentration levels, small changes in sample extraction and 
preparation as well as instrumental response have a greater effect on lower 
concentrations than higher concentrations.  This trend was also seen with DZ, FLU, and 






5.3.6 Dilution Integrity 
 
 Dilution integrity was determined by repeating bias and precision studies on 
diluted samples.  Samples were prepared at 1000 ng/mL and then diluted to 1:5 (200 
ng/mL) and 1:10 (100 ng/mL).  Five samples were prepared and analyzed in triplicate 
for each concentration.  Both dilution sets maintained requisite identification criteria for 
all analytes except for AEME.  Excluding AEME, the bias ranged from -10.6 to 14.0%, 
within-run precision from 0.7 to 2.0%, and between-run precision from 1.7 to 7.4%.  The 
bias for AEME in the 1:10 dilution set was higher than ±20%.  Future dilutions should be 
prepared at 1:5.  The summarized data can be seen in Table 49 and Table 50. 
 
Table 49 – Dilution Integrity for Cocaine and Metabolites in RCM 
 
Analyte COC AEME BZE CE EME mHC 
 
NC 
        
 1:5 (1000:200 ng/mL) 
Bias (%) -3.5 -19.8 -5.9 5.5 2.7 14.0 1.2 
Within-Run (%) 0.7 1.2 1.4 1.3 1.2 1.5 1.3 
Between-Run (%) 4.3 7.4 4.7 4.7 4.4 5.4 4.6 
        
 1:10 (1000:100 ng/mL) 
Bias (%) -4.9 -25.3 -9.0 4.1 -1.0 9.8 -1.0 
Within-Run (%) 1.5 1.3 1.4 1.3 2.0 1.6 1.2 













    
 1:5 (1000:200 ng/mL) 
Bias (%) -1.0 9.0 -7.5 
Within-Run (%) 1.6 1.5 1.2 
Between-Run (%) 4.4 5.2 4.7 
    
 1:10 (1000:100 ng/mL) 
Bias (%) -4.1 5.4 -10.6 
Within-Run (%) 1.5 1.5 1.1 
Between-Run (%) 2.8 2.4 2.7 
 
 
5.3.7 LOD and LOQ 
 
LOD and LOQ were defined in Sections 1.5.7 and 1.5.8, respectively.  Values for 
COC, FENT, and metabolites ranged from 0.100 to 10 ng/mL and are reported in Table 
2.  COC and BZE achieved the lowest LOD and LOQ values at 0.1 ng/mL.  mHC, NC, 
FENT, and DESP maintained RT, peak shape, and ion ratios at 0.1 ng/mL, satisfying 
LOD requirements but bias exceeded ± 20%.  The LOQ requirements were fulfilled at 
0.25 ng/mL for these analytes.  All of the analytes of interest had LOQ values ≤ 0.5 
ng/mL with the exceptions of AEME and EME.  Both of these analytes eluted near or 
possibly with the solvent front.  This caused ionization to be incomplete as well as 
inconsistent, which resulted in higher LOD and LOQ values.  The lack of a deuterated 




Stability was assessed by evaluating freeze-thaw stability as well as processed 




conducted over three cycles at three concentrations 200 ng/mL (high), 10 ng/mL 
(medium), and 0.5 ng/mL (low).   
COC, BZE, CE, NC, and NFENT remained stable for all three concentrations and 
FT cycles.  EME was stable for all three cycles at the high and medium concentrations, 
however the low concentration sample was below the LOQ of EME.  Fentanyl was 
stable for FT1, FT2, and FT3 for high concentration, and FT1 and FT2 for medium 
concentration.  All concentrations were stable for FT1 and FT2 for mHC and DESP.  
With the exception of AEME, most analytes should remain stable through two complete 
freeze-thaw cycles at high and medium concentrations.  Experimental values for AEME 
were well above the theoretical values for all concentrations and cycles.  Future 
analyses involving quantitation of AEME should therefore be conducted immediately 
after preparation and not preserved by freezing.  
The stability of processed samples was studied at two concentrations 200 ng/mL 
(high) and 5 ng/mL (low) in triplicate over the course of 60 hours.  Samples were taken 
every 12 hours to accommodate the sample run time.  For 200 ng/mL, cocaine and 
metabolites remained stable until the 48 hour mark.  At 60 hours, however, mHC 
dropped below the 160-240 (±20%) ng/mL range (dashed lines).  Error bars were 
determined at the 95% confidence interval.  This was depicted in Figure 33.  Fentanyl 
























































































At low concentration (5 ng/mL), COC and metabolites remained stable for at 
least 60 hours (Figure 35) as did FENT and metabolites (Figure 36).  Error bars were 
determined at the 95% confidence interval, and dashed lines represent the ±20% range. 
The stability of AEME was not assessed at the low concentration because it was below 
the LOQ for that particular metabolite.  Based on these studies, samples should remain 
stable for at least 48 hours.  This was an important feature of method validation, 


































































































 An LC-MS/MS method was developed and validated for the detection, 
identification, and quantitation of COC, FENT, and metabolites extracted from RCM.  
This method can be used to apply the analyte degradation and biotransformation 
studies outlined in Chapter 4 for DZ and FLU to COC, FENT, and other drugs of abuse 











6.1.0 Summary of Research 
 
A review of previously published literature and research revealed that bacterial 
species were capable of metabolizing complex chemical substances.  Many of the 
biotransformation applications discussed in Chapter 1 resulted in novel and interesting 
applications toward agricultural and environmental contaminant reduction or elimination, 
greater insight into the effectiveness of pharmaceutical compounds, and new 
applications of isolated bacterial enzymes.   
Some of these same bacterial species are native to the human GI tract and play 
an active role in the postmortem decomposition process.  These species have potential 
to cause biotransformations that affect the ratios of compound-to-metabolite 
concentrations within the human body.  Such effects have rarely been considered or 
evaluated, but they have potential to supply valuable information, especially concerning 
compound identification and confirmation. 
The purpose of this research was to develop methodology, investigate the effects 
of GI bacteria on drugs of abuse, and to compare metabolites to those recovered in 
human metabolic studies.  Analytes of interest and (metabolites) were DZ (NDZ, OX, 
TZ), FLU (7AM, NDES), COC (AEME, BZE, CE, EME, mHC, NC), and FENT (NFENT, 
DESP).  All of these compounds are scheduled drugs of abuse controlled by the DEA, 




The analytes and selected metabolites were also chosen based on the commercial 
availability of certified reference standards. 
Bacterial growth and preparation techniques were optimized and discussed in 
Chapter 2, which included nutrient medium evaluation and selection, establishment and 
maintenance of anaerobic conditions, preparation of frozen stock cultures, viable 
bacterial enumeration, and a review of cellular lysis techniques.  E. coli, B. fragilis, and 
C. perfringens were selected because they are prominent species, viable under the 
limited oxygen conditions found in the human GI tract and thereby capable of growth 
and metabolism.  RCM was chosen as the nutrient medium because it was able to 
support the growth and proliferation of all three bacterial species.  Anaerobic conditions 
were established using an anaerobic chamber fitted with purge gases that worked with 
a catalyst system to convert residual oxygen to H2O.  Maintenance of these conditions 
was critical in supporting bacterial growth, particularly for B. fragilis and C. perfringens, 
anaerobic species whose growth and survival were inhibited in the presence of oxygen.   
Preparation of a frozen stock culture for each species provided an ample supply 
of bacteria for biotransformation studies, and the plate count procedure gave an 
estimation of the viable bacteria in inoculated samples.  The CFU/mL counts were 
within the ranges of viable populations found in the human GI tract, specifically the 
ileum (105 - 108) and colon (1010 - 1012) as reported by the NIH.45  Several cellular lysis 
methods were evaluated, but all were dismissed to maintain the accuracy and integrity 
of the optimized experimental conditions. 
To investigate the effects of the selected bacterial species on DZ and FLU, an 




these benzodiazepine compounds as well as their respective metabolites.  The method 
was fully validated to ensure analysis was performed and interpreted with reliability and 
certainty.  Analytes were recovered from RCM via SPE.  To date, similar methods of 
analysis and quantitation of drugs of abuse in a nutrient medium matrix have not been 
published.  Method development and validation were discussed in Chapter 3.   
Validation was based on definitions and parameters established by the ICH,25, 89 
SWGTOX26, and DHHS, FDA, CDER, and CVM.27  Linearity was addressed by creating 
a calibration model for each of the analytes in RCM.  Specificity was evaluated through 
matrix and internal standard interference studies, ionization enhancement/suppression, 
ME, RE, and PE.  The carryover effects, accuracy, bias, precision (within-run precision), 
repeatability (between-run precision), LOD, LOQ, range, dilution integrity, freeze-thaw 
stability, processed sample stability, and robustness of the methods were also 
assessed.   
Dilution integrity was particularly important because biotransformation samples 
were spiked at 1000 ng/mL, while the upper range of the method was only 500 ng/mL.  
Dilutions were prepared at 1:2 and 1:5.  Both sets met the requirements of maintaining 
acceptable retention time, peak shape, an ion ratios as well as accuracy, bias, and 
within-run and between-run precision.  Processed sample stability was also important.  
Analytes were incubated for 48 hours as part of the experimental application process.  
In addition, samples were analyzed in large batches and with replicate analysis which 
prolonged the time between introduction to the autosampler and LC-MS/MS analysis.  
The processed sample stability study provided that samples would maintain stability for 




Following validation, the method was applied to assess the specific effects of E. 
coli, B. fragilis, and C. perfringens on DZ and FLU, which were discussed in Chapter 4. 
Experiments explored the effects of environmental conditions on analyte blanks as well 
as bacterial inoculates. Biotransformation studies explored the effects of individual 
species as well as a mixed culture on the benzodiazepines compounds under anaerobic 
conditions.   
A series of bacterial blanks were prepared in RCM with aliquots of E. coli, B. fragilis, 
C. perfringens, or a mixed culture without analytes of interest.  These samples were 
incubated under experimental conditions.  None of the bacterial specimens produced 
interferences with the target analytes that satisfied the requirements for peak shape, 
retention time, ion ratios, and LOQ. 
Analyte blanks were also examined.  RCM spiked with either DZ or FLU was 
incubated and analyzed.  Mass balance data for DZ suggested it undergoes a partial, 
unassisted degradation when incubated under experimental conditions.  However, NDZ, 
OX, nor TZ registered an increase from pre- to post-incubation concentrations.  The 
proposed degradation product was therefore unidentified.  
RCM samples prepared for biotransformation studies were spiked with an 
analyte of interest at 1000 ng/mL as well as either E. coli, B. fragilis, C. perfringens, or 
mixed culture.  Pre- and post-incubation aliquots were taken for analysis and the 
change in concentration results were calculated.   
Analysis of the effects of E. coli on DZ concentration produced an average DZ 
concentration difference that was slightly greater than what was observed in DZ blank 




increase from pre- to post-incubation concentrations.  The mass balance discrepancies 
between blank and biotransformation study samples indicated that there may be 
additional factors contributing to the transformation of DZ when incubated with E.coli.   
Similar results were seen in the B. fragilis  biotransformation studies as well.   
In both cases RCM samples showed the marked turbidity indicative of prominent 
bacterial growth.  A possible explanation for the discrepancy between DZ blank and E. 
coli and  B. fragilis biotransformation samples is that DZ was being converted to a 
compound other than the monitored human metabolites.  In this case, E. coli  and B. 
fragilis  would have possessed a specific enzyme or combination of enzymes capable of 
cleaving DZ to form alternative metabolites.  It is unclear whether E.coli and B. fragilis 
would have employed the same enzyme or if the DZ conversion was attributed to 
species-specific enzymes.  Additional experimental and literature review may offer 
some guidance toward alternative metabolites. 
Similar to the studies performed on E. coli and B. fragilis, there were negligible 
changes in concentration detected for NDZ, OX, and TZ in samples inoculated with C. 
perfringens.  However, there was minimal change in DZ concentration as well.  These 
findings supported the theory of E. coli and B. fragilis were responsible for the 
concentration discrepancies between the DZ drug blanks and their respective 
biotransformation studies.  The small change in DZ concentration, however, was unique 
to C. perfringens incubations.  All samples were prepared and incubated under the 
same circumstances and a loss of DZ concentration comparable to at least that of the 




it is possible that introduction of C. perfringens stabilized the analyte and prevented 
degradation. 
The effects of the mixed culture studies resulted in post-incubation 
concentrations similar to those seen in C. perfringens.  This supported the supposition 
that the presence of C. perfringens stabilized the analyte and prevented the proposed 
degradation by E. coli and B. fragilis. 
Analysis of the FLU drug blanks exhibited a decrease in concentration.  
However, unlike what was observed in the DZ blank experiments, there was a 
corresponding increase in concentration for the 7AM metabolite in the post-incubation 
samples that accounted for some of the FLU loss.  E. coli, B. fragilis, C. perfringens, 
and the mixed culture were all capable of transforming FLU to 7AM to some extent.  
Data was consistent with that published in experiments by Robert and Drummer16,17 in 
which they studied effects of GI bacteria on three benzodiazepine compounds in blood.  
They discovered that all three compounds were converted to their respective 7-amino 
metabolites though the rate of conversion varied amongst the different species.   
E. coli was capable of converting a portion of the FLU to 7AM between pre- and 
post-incubation samples, which accounted for some of the FLU loss. However, not all of 
the original FLU concentration was recovered as 7AM as seen in the mass balance of 
the conversion.  This could potentially be attributed to FLU being transformed into an 
additional metabolite that was not monitored such as 3-hydroxyflunitrazepam.  Another 
possibility was that 7AM itself was being converted to metabolites 7-acetamino-




were presented in Figures 23 and 24.  Further analysis would be required to determine 
the presence and identity of these or other potential bacterial metabolites.   
B. fragilis, C. perfringens, and the mixed culture completely transformed the pre-
incubation FLU concentration in all samples.  The majority was recovered as 7AM in the 
post-incubation samples, but there was some concentration discrepancy.  The 
metabolites proposed above were the most likely candidates for minor metabolites, but 
further analysis would be required. 
An additional drugs of abuse and (metabolites) method was developed and fully 
validated for COC (AEME, BZE, CE, EME, mHC, and NC) and FENT (NENT and 
DESP) in RCM, the results of which were discussed in Chapter 5.  It was validated in 
similar fashion to the method for DZ and FLU.  As with the DZ and FLU method, dilution 
integrity was particularly important.  Dilution integrity dictated that samples would be 
diluted 1:5 prior to analysis.  Processed sample stability was likewise an important 
feature of the method validation.  The processed sample stability study provided that 
samples would maintain stability for 48 hours after extraction from RCM.  This method is 




6.2.0 Research Implications 
 
 
The experimental results served as a pilot study and proof of concept.  Though 
the ability of bacterial species to transform complex chemical substances has been 
previously studied, this methodology offers several distinct advantages.  Much of the 




from volunteer human subjects.  The presented methodology utilized bacterial species 
for experimental purposes which eliminated the ethical considerations and guidelines 
required for animal and human research endeavors.  
The methodology was also cost-effective.  Preparation of frozen stock cultures 
for each bacterial species provided a theoretically endless supply of specimens for 
transformation studies, which aided in keeping the materials costs to a minimum. 
Extraction procedures, a narrow bore column, and low flow rate for instrumental 
analysis minimized solvent consumption and hazardous waste production, which was 
both cost-effective and environmentally friendly.  In addition, the streamlined 
experimental approach allowed for quantities of experimental variations to be performed 
in unison, which conserved time. 
The presented experimental methodology serves as a template for further 
exploration of the effects of bacterial species on complex chemical compounds.  The 
principles behind experimental design and analysis can be adapted and applied to a 
realm of possibilities.  But perhaps the most important feature is the ability to streamline 
experimental procedures.  
These methods could be applied concurrently to determine bacterial species 
candidates for biodegradation of agricultural and environmental contaminants, such as 
pesticides, explosives, and chemical warfare agents.  They can also be utilized to 
isolate and repurpose native bacterial enzymes.  This has seen promise in the medical 
field as well as in sensors for drugs of abuse detection.  The methods can likewise be 




drugs of abuse.  In addition to expanding the analytes of interest, the applications can 
easily be expanded to include alternative bacterial species as well. 
Ultimately, this methodology would be ideal to study compounds that are too 
toxic or lethal for animal and human metabolic investigations.  This would be particularly 
useful in military explorations of exposure to incapacitation and chemical warfare 
agents.  In many of these instances, victims do not survive long enough for the 
compound to undergo human metabolic conversions.  Since bacterial species are 
capable of transmigration postmortem as well as biotransformation of complex chemical 
compounds, their metabolites could provide information that would be useful in agent or 
compound identification. 
 
6.3.0 Future Work 
 
 
COC and FENT are of forensic importance.  Future works should begin with the 
application of the validated method for COC and FENT discussed in Chapter 5.  These 
analytes can easily be incorporated into analyte blank and biotransformation studies 
described in Chapter 4.  Development of the presented methodology and analysis of 
results presented several other experimental opportunities that could expand upon and 
contribute to this area of research.   
Kinetic studies could be performed to determine the degradation rate of DZ and 
FLU in the analyte blank samples discussed in Chapter 4.  Proposed experimental 
design could be based upon processed sample stability studies performed as a part of 
method validation (Section 3.3.8), where an aliquot of analyte blank is taken at defined 




via LC-MS/MS.  The change in analyte concentration over time would provide an 
estimate of the unassisted degradation of DZ and FLU under experimental conditions.  
This conversion rate could also be compared to that calculated for each analyte when 
incubated with  E. coli, B. fragilis, C. perfringens, and mixed culture in biotransformation 
studies.  Kinetic studies could be conducted for COC and FENT conversions as well.  
Identification of the other degradation and biotransformation products would likewise be 
an important contribution to the DZ and FLU experiments. 
Robertson and Drummer studied the effects of pH and temperature on the 
compound-to-metabolite rate of conversion, which were discussed in Section 1.1.3.  
Changes in the environmental and incubation conditions could be applied to study the 
conversion rate of FLU to 7AM using the methods provided in Chapters 3 and 4 as well 
as the proposed kinetic studies.16,17  
The presented experimental methodology provides a template for further 
exploration of the effects of bacterial species on complex chemical compounds.  These 
techniques can be expanded to include other drugs of abuse.  Preliminary methods 
have been developed for methadone (Appendix F) and methamphetamine (Appendix 
G). These methods utilize the same HPLC buffer system and could be combined for 
convenience, validated, and applied to the biotransformation studies.  Other compounds 
of interest such as pharmaceuticals, environmental contaminants, and explosives could 
also be incorporated for analysis. 
Table 4 lists the prevalent bacteria in the lower GI tract, all of which could be 
incorporated into the methodology.  Experiments could also be expanded to include 




facultative anaerobic and anaerobic species.  However, experiments could be expanded 
to include aerobic species as well.  E.coli could be used to compare the effects of 
aerobic vs. anaerobic conditions on biotransformation products and rates. 
 This method was applied to biotransformation studies of the benzodiazepine 
analytes by GI bacteria.  This method and application served as a proof of concept, 
proving that this type of experimentation and methodology are capable of studying 
bacterial metabolism of complex compounds.   The methodology can expand to 
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Appendix A – Calibration Curves for Diazepam, Flunitrazepam, and 












































Appendix B – Calibration Curves for Diazepam, Flunitrazepam, and 




































































Appendix C – Optimized Precursor & Product Ions for Diazepam, 
Flunitrazepam, and Metabolites 
 
 












 107 29 285.1 193.0 
DZ 107 25 285.1 154.0 
 107 25 285.1 222.1 
 107 45 285.1 91.0 
 112 25 271.1 140.0 
NDZ 112 25 271.1 208.0 
 112 25 271.1 165.0 
 112 37 271.1 91.0 
 112 17 287.1 241.0 
OX 112 9 287.1 268.9 
 112 37 287.1 104.0 
 112 36 287.1 162.9 
 107 17 301.1 255.0 
TZ 107 5 301.1 282.9 
 107 41 301.1 177.0 
 107 33 301.1 193.0 
 












 135 21 314.1 268.1 
FLU 135 33 314.1 239.1 
 135 49 314.1 183.1 
 135 33 314.1 211.0 
 140 25 284.1 135.0 
7AM 140 17 284.1 227.1 
 140 29 284.1 226.2 
 140 29 284.1 240.1 
 125 21 300.1 253.9 
NDES 125 37 300.1 197.9 
 125 33 300.1 225.1 





Appendix D – Calibration Curves for Cocaine, Fentanyl, and 


































































Appendix E – Optimized Precursor & Product Ions for Cocaine, 
Fentanyl, and Metabolites 
 
 












 96 13 304.2 182.0 
COC 96 20 304.2 82.0 
 96 20 304.2 105.0 
 96 20 304.2 150.0 
 96 20 182.1 118.0 
AEME 96 20 182.1 91.0 
 96 17 182.1 122.0 
 96 13 182.2 150.4 
 96 13 290.1 168.0 
BZE 96 20 290.1 104.9 
 96 20 290.1 82.0 
 96 20 290.1 150.0 
 96 13 318.2 196.0 
CE 96 20 318.2 82.0 
 96 20 318.2 150.0 
 96 20 318.2 108.0 
 96 13 200.1 182.0 
EME 96 20 200.1 82.0 
 96 20 200.1 150.0 
 96 20 200.1 108.0 
 96 13 320.2 182.0 
mHC 96 20 320.2 82.0 
 96 20 320.2 150.0 
 96 20 320.2 120.9 
 96 9 290.1 168.0 
NC 96 17 290.1 136.0 
 96 20 290.1 108.0 


















 130 19 337.2 188.0 
FENT 130 43 337.2 105.0 
 130 50 337.2 79.0 
 130 31 337.2 132.0 
 100 15 233.17 84.0 
NFENT 100 43 233.17 55.1 
 100 31 233.17 93.9 
 100 50 233.17 128.6 
 100 31 281.2 105.0 
DESP 100 15 281.2 188.0 
 100 50 281.2 79.0 






Appendix F – Calibration Curves for Cocaine, Fentanyl, and 






































































Methadone (MetD) is a synthetic narcotic and Schedule II drug of abuse.24  It is 
used for medical purposes (Dolophinel®) in the detoxification and as a maintenance 
treatment for those addicted to opiates.  Methadone can be administered as a pill, 
orally, or by injection, and is also referred to as Amidone, chocolate chip cookies, 
fizzies, Maria, Pastora, and wafer.   
Dependence is a common health effect for those who abuse the drug.  
Withdrawal symptoms include anxiety, tremors, and vomiting. Overdose can lead to 


















Metabolic Pathway of Methadone51,70,71,90-94 51,90,91,70,71,92,93,94, ,95,96,97 
   
   




   
   
   




   
   








This research focused on specific metabolites 2-Ethylidene-1,5-Dimethyl-3,3-
Diphenylpyrrolidine (EDDP) and 2-Ethyl-5-Methyl-3,3-Diphenylpyroline (EMDP).  
Methadone-d3 (MetD-d3) and 2-Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidine-d3 








Standards were obtained from Cerilliant as 1mg/mL for MetD, EDDP, and EMDP 
and as 100μg/mL concentration for MetD-d3 and EDDP-d3.  The following table lists the 
MRM transitions for methadone and metabolites found in the reference literature.  
 
Methadone - Compounds, Metabolites, Precursor/Product Ions 
 
Agilent’s MassHunter™ Optimizer Software was used to identify the optimal 
quantifier and qualifier MRM transitions for methadone and its metabolites under the 
dissertation research experimental conditions. These values can be found in the 
following Table. 
 












MetD-d3 100 15 313.2 268.1 
 100 27 313.2 105.0 
 100 15 310.2 265.0 
MetD 100 27 310.2 104.9 
 100 50 310.2 77.0 
 100 19 310.2 57.0 
 160 31 278.2 234.0 
 160 19 278.2 249.1 
EDDP 160 35 278.2 186.0 
 160 43 278.2 219.0 
     
 130 19 264.2 235.0 
EMDP 130 50 264.2 115.0 










Methamphetamine (MetA) is a CNS stimulant and classified by the DEA as a 
Schedule II drug of abuse.24  It is known as Desoxyn® when used for medicinal 
purposes.  Methamphetamine can be snorted, smoked, ingested, or injected. Some of 
the many street names include bikers, black beauties, chalk, chicken feed, coffee, 
crank, crystal, glass, go-fast, ice, quick, shards, speed, Tina, trash, and yellow barn. 
Addiction is common for those who abuse the drug.  Effects include anxiety, 
confusion, paranoia, hallucinations. Methamphetamine use has also been associated 
with aggressive and violent behavior.  Health risks include elevated blood pressure, 
body temperature, respiration, and heart rate, as well as anorexia, convulsions, dental 





Metabolic Pathway of Methamphetamine51,98-102  51,98,99,100,101, 102   
 
   
 
  
     


















     
 
 
This research focused on specific metabolites p-hydroxymethamphetamine 
(pHM) and amphetamine (AMP). Methamphetamine-D5 (MetA-d5) and amphetamine-
d5 (AMP-d5) were used as internal standards.   
Standards were obtained from Cerilliant in the 1mg/mL concentration for MetA 
and AMP and in the 100μg/mL concentration for MetA-d5 and AMP-d5.   The standard 
for pHM was obtained from Sigma Aldrich as a 25mg sample.  Agilent’s MassHunter™ 









transitions for methamphetamine and its metabolites under the dissertation research 
experimental conditions. These values can be found in the following Table. 
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 100 19 150.1 90.9 
MetA 100 50 150.1 65.0 
 100 50 150.1 77.0 
 100 23 150.1 135.0 
 100 19 166.1 106.9 
pHM 100 43 166.1 77.0 
 100 21 166.1 121.9 
 100 23 166.1 151.0 
 100 19 136.1 91.0 
AMP 100 39 136.1 65.0 
 100 27 136.1 67.0 
 100 15 136.1 96.8 
 
